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Abstract
We discuss methods for comparing eects of two treatments A and B. We investigate
the performance of response-adaptive (RA) and covariate-adjusted response-adaptive
(CARA) designs in multi-center clinical trials. First, we discuss applying RA designs
to maximize the well-being of participating patients in multi-center clinical trials. We
assume that the centers are selected from a large population of centers and develop a
generalized linear mixed model (GLMM) to examine the treatment eect. The asymp-
totic properties of the maximum likelihood (ML) estimators of model parameters are
derived using the inuence function method. We veried their theoretical properties
through simulation studies. The techniques are then applied to a real data that were
obtained from a multi-center clinical trial designed to compare two cream prepara-
tions (active drug/control) for treating an infection. Secondly, we investigate the e-
ciency for estimates of model parameters and ethics for participating patients among
RA, CARA, and completely randomized (CR) designs for a generalized linear model
(GLM). We consider the logit model to measure eciency and ethics. Furthermore,
we showed that ML estimators of GLM parameters are consistent and asymptotically
follow multivariate normal distribution for adaptive designs. A simulation study was
conducted to verify these theoretical results. Finally, we provide a justication of why
asymptotic results for Wald-type tests for adaptive designs can be used. We proved
that the choice of adaptive designs aects the statistical power of hypothesis testing
via these quantities: the target allocation proportion, the bias of the randomization
procedure from the target, and the variability induced by the randomization process.
Moreover, we showed that the statistical power increases when the design variability
decreases for a covariate in a logit model. Our theoretical ndings are veried by
simulation results.
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Chapter 1
An Overview of Statistical
Modelling and Adaptive Designs in
Clinical Trials
In the past several decades, much research has been conducted in developing therapy
methods and drug development through clinical trials. Researchers have been inter-
ested in acquiring an ecient procedure for comparing new treatments with existing
ones. These procedures include the design criteria, which consist of treatment assign-
ments to patients, and comparisons of treatment methods characterized by statistical
approaches for identifying the best treatment. At the initial stage of a clinical trial,
the selection of a suitable design for treatment assignment is of primary concern. It is
also important to identify a suitable model that will be used for data analysis at the
initial stage of the experiment. Thus is however challenging due to lack of sucient
data at the beginning of an experiment. In fact, sucient data usually is available at
the end of a clinical trial. Given sucient data for statistical inference, one can choose
a simple and an ecient model, for future usage, from a set of candidate models. For
2example, the Akaike Information Criterion (AIC) or the Bayesian Information Crite-
rion (BIC) can be used to choose a model to describe a given data set. Furthermore,
the Quasi-AIC (QAIC) can be applied as a model selection criterion when the estima-
tion of regression parameters are based on Quasi-Likelihood (QL) methods [Burnham
and Anderson (2002)]. Thus, the absence of sucient data at the initial stage of the
trial makes the identication of the best model a challenging task.
In this thesis, we investigate some designs for treatment assignment and develop a
new approach for conducting statistical inference for the purpose of comparing two
treatments, say A and B, in multi-center clinical trials. In particular, we will investi-
gate the performance of Response-Adaptive (RA), and Covariate-Adjusted Response-
Adaptive (CARA) designs in maximizing the well-being of participating patients while
collecting responses and associated covariates and assigning treatments to patients at
participating medical centers. The purpose is to optimise the resources while having
an ecient statistical inference procedure at the end of the clinical trial. Throughout
this thesis, treatment A will be considered an experimental treatment and treatment
B will be an existing treatment. Burnham and Anderson (2002) notes that although
an ideal data set cannot be collected to explain the behavior of treatments A and
B, the experimenter should be cautious when collecting data for this purpose. For
instance, an experimenter has to be cautious with the type of response (binary, count,
continuous, and longitudinal) and covariates to be collected, since the correct identi-
cation of the behavior of treatments A and B depends on the data collected.
According to Sverdlov (2016), clinical trials typically have several goals, which can be
3divided into two main objectives:
objective 1 : have an ecient statistical inference at the end of a clinical trial, and
objective 2 : respect the well-being and dignity of participating patients.
(1.1)
According to Sverdlov (2016), eciency generally refers to the power of testing a re-
search hypothesis in clinical trials, while ethics often concerns patients assigned to
unsafe or inferior treatments. An ecient statistical inference is necessary for the
well-being of future patients. Sverdlov (2016) refers to the conict between these two
objectives as \individual versus collective ethics". It is clear that statistical power
increases when sample size is larger. However, increasing the sample size results in
the following: (i) raising the cost of an experiment and (ii) increasing the number of
patients in randomization.
Suppose a clinical trial is conducted in J medical centers, which are randomly selected
from a large number of medical facilities. Furthermore, suppose that the responses are
binary and denoted by Yij. Let n

j be the total number of patients who are recruited
and assigned to one and only one of the two treatments in center j, j = 1; 2;    ; J and
n =
JX
j=1
nj , where n is the total number of participating patients. Dene the response
Yij and treatment assignment XijA to patient i in center j, for i = 1; 2;    ; nj and
j = 1; 2;    ; J by
Yij =
8>>>><>>>>:
1 if treatment is
a success,
0 otherwise,
and XijA =
8>>>><>>>>:
1 if patient i in center j
is assigned to treatment A,
0 otherwise.
(1.2)
Although the comparison of treatments eect is the primary goal, treatment eect can
4be eciently compared when suitable covariates are included in a proper model. Some
typical covariates are gender, smoking status, age, cholesterol level, chronic conditions,
and so on. The smoking status of a patient can inuence the response of medical care
for cancer, whereas the patients' chronic disease, for instance high blood glucose level
or cholesterol level, can aect the response of medical care for hypertension. Suppose
that K number of categorical covariates other than treatment, say v1; v

2;    ; vK , are
collected in the clinical trial, and each covariate has a nite number of levels, where
vk has Lk + 1 levels: say v

k0; v

k1;    ; vkLk for k = 1; 2;    ; K. Then, we can dene a
set of dummy variables based on the reference category vk0, k = 1; 2;    ; K, for each
covariate. Without loss of generality, let Z0ij = (Zij1;    ; Zijp) be the p dimensional
vector of dummy variables corresponding to the covariates of patient i in center j,
where p =
KX
k=1
Lk and each component of Zij has binary levels, for i = 1; 2;    ; nj
and j = 1; 2;    ; J . These dummy variables represent the characteristic of patients.
Thus, Zij is the covariates of patient i in center j.
Sverdlov (2016) notes that one can assume a starting model for a clinical trial. In
what follows, we add center eects to Sverdlov (2016) initial model because the ex-
periment in this thesis is conducted at multiple clinics. Therefore, we assume that
Yij, conditional on xijA, zij, and uj follows the statistical model,
E(YijjxijA; zij; uj) = g(; xijA; zij; uj); (1.3)
for i = 1; 2;    ; nj and j = 1; 2;    ; J , where g(:) is a regression function; uj is the
eect of center j;  is a vector of model parameters which includes the main eect of
treatment A compared to treatment B, the main eects of other covariates, and the
eects of treatment by covariate interactions.
5In this thesis, we wish to conduct ecient statistical inference of the treatment eect,
in the following areas:
(i) The selection of an appropriate regression function g.
The function g in (1.3) can be selected from existing binary link functions such
as logit, probit, cauchit, and complementary log-log [See McCullagh and Nelder
(1989)]. The maximum likelihood (ML) method for parameter estimation rely
on a link function. On the other hand, identifying the behavior of collected
data using either the Quasi-Likelihood (QL) or the Generalized Quasi-Likelihood
(GQL) method does not require a full model assumption to conduct statistical
inference. Also, a nonparametric method could be used to conduct inference at
end of the clinical trials [Sverdlov (2016)].
(ii) The inclusion of variables in linear predictor.
In our analysis, we will determine the types of variables, such as covariate and
center eect, that should be incorporated into the linear predictor. Depending
on the variables included in the model, we will use the Generalized Linear Model
(GLM), or the Generalized Linear Mixed Model (GLMM) or the Generalized
Linear Model with xed center eects to analyze the data set.
(iii) The estimation of model parameters.
A suitable method will be implemented to estimate the model parameters.
Some methods in literature are Maximum Likelihood (ML), Method of Mo-
ments (MM), Quasi-Likelihood (QL) [see Wedderburn (1974); McCullagh and
Nelder (1983)], and Generalized Quasi-Likelihood (GQL) [see Sutradhar (2003)].
In this thesis, we have applied the ML method. We also introduced a new ap-
proach in x 2.3 for computing MLE based on the concept of inuence functions.
6(iv) Hypothesis testing.
After estimating the model parameters, we will conduct hypothesis testing to
identify whether treatment A is signicantly dierent from treatment B for a
given signicance level. For example, a Likelihood-Ratio test, a Score test, or a
Wald test will be implemented to test regression parameters. Furthermore, the
power of the test for a given size of the test will be computed and checked with
the experimenter's predetermined value of power. Also, if the computed power
does not attain this threshold value, then we will increase the sample size until
this threshold value is achieved.
(v) Interpretation of results.
Finally, the results will be interpreted after reaching the experimenter's thresh-
old value of power. Also, the best treatment will be identied at the end of the
clinical trial.
1.1 Designs in Clinical Trials
Friedman et al. (2015) dene \a clinical trial as a prospective study comparing the
eects and value of intervention(s) against an existing treatment in human beings".
For instance, in a clinical trial to compare a new treatment, say A against an existing
treatment, B, treatment A is considered the intervention and treatment B as the
existing. In statistics, the variable treatment is an example of a controllable variable
or factor since the values or levels of the treatments can be set by the experimenter.
Thus, we dene controllable variables or factors as any variable that might inuence
the response whose values the experimenter can set. That is, by controllable variable
we mean that the experimenter can decide the type of randomization to apply in
selecting a design. In contrast, covariates are variables that might aect the outcome
7but experimenters cannot control, nonetheless, these covariates can be measured.
The concept of selection of designs was introduced by James Lind in a clinical trial,
which was conducted in 1747 [Dunn (1997)] involving six groups of food, which were
suspected by Lind, to cure scurvy. However, in this experiment, there was no evidence
that the designs were chosen with a pre-specied objective of conducting valid infer-
ence. According to Oyet (1997), the principle of optimal designs was rst proposed by
Smith (1918). In these optimal designs, a criteria is applied to choose designs for the
purpose of conducting ecient statistical inference with minimum sample size, which
will reduce the cost of experimentation.
When constructing optimal designs, randomization is commonly applied to lessen ex-
perimental bias. In fact, the principle of randomization introduced by Ronald Fisher
in 1926 was systematically applied in agriculture. Thus, completely randomized (CR)
designs or equal allocations is a randomization method used to avoid selection or
experimenter bias during treatment allocation [Shao and Yu (2013)]. Furthermore,
although some pivotal covariates are unknown to the experimenter, we may be able
to estimate the treatment eect eciently by applying randomization because ran-
domization reduces experimental bias. In fact, complete randomization is used in
equal allocation. However, \equal allocation may result in severe imbalance not only
between the treatment groups but also across covariates" [Shao and Yu (2013)]. But,
balances will be asymptotically achieved between the treatment groups as well as
across covariates. In fact, reducing experimental bias is the pre-selected objective
of equal allocation. Instead of the concept of complete randomization, it is possi-
ble to apply other randomization methods to quickly achieve objective 1 in (1.1).
For instance, accrued information is utilized in adaptive designs to avoid complete
8randomization. So, we discuss the concept of adaptive randomization in the next
section.
1.1.1 Adaptive Designs
Adaptive designs were introduced to overcome disadvantages of equal allocation with-
out completely eliminating the principle of randomization. So, these designs impose
some restrictions in the selection process while maintaining the spirit of randomiza-
tion. The history of treatment assignments in an experiment is used to select the next
assignment in restricted randomization, which is a member of the family of adaptive
designs. In adaptive designs, accumulated data are used to create these restrictions.
As a result, restricted randomization is an approach to maintain balance between
treatment groups when sample size is small. Bailey (1987) had noted that the con-
cept of restricted randomization was developed by Yates (1948) and Youden (1972).
The main purpose of restricted randomization is to achieve objective 1 in (1.1).
However, this randomization was not based on the concept of optimal designs.
Contrary to the objective of restricted randomization, the concept of adaptive designs,
rst introduced by Thompson (1933) was to obtain data for the purpose of respecting
the well-being and dignity of participating patients. In 2010, the US Food and Drug
Administration (FDA) recommended some guidelines for applying adaptive designs
in clinical trials. The FDA (2010) notes that modications can be made to the design
based on interim analysis of already collected data before collecting data for nal
analysis. Modication can be made to the following:
(i) randomization procedure,
(ii) total sample size of the study (including early termination), and
9(iii) analytic methods to evaluate the endpoints (e.g., covariates of nal analysis,
statistical methodology, Type I error control).
These adaptive designs are not only applied to choose the best treatment, but they are
also used to nd the best dose level for a group of patients having specic covariates,
because small dosage amounts may not signicantly improve the disease status of a
patient. On the other hand, a large dosage may produce dangerous side eects [FDA
(2010)]. Adaptive designs are also used in the development of medical device [FDA
(2015)].
There are currently a wide variety of adaptive designs in the literature. The dier-
ences in these designs are determined by their pre-selected objectives. For instance,
Covariate-Adaptive (CA), Response-Adaptive (RA), Covariate-Adjusted Response-
Adaptive (CARA), Response-Adaptive Covariate-Adjusted (RACA) designs are mem-
bers of the family of adaptive designs. Rosenberger et al. (2012), states that \an
important class of clinical trial designs is adaptive randomization, which is a change
in randomization probabilities during the course of the trial to promote multiple ex-
perimental objectives, while protecting the study from bias and preserving inferential
validity of the results". Next, we describe these adaptive designs based on the accru-
ing data and randomization of treatment assignments.
A sigma algebra is a set of all possible information generated by random variables.
For i = 1; 2;    ; nj , let us assume that Xij = (X1jA; X2jA;    ; XijA), and Yij =
(Y1j; Y2j;    ; Yij) are the sigma algebras generated by treatment assignments, and re-
sponses respectively in center j, j = 1; 2;    ; J . Thus, for i = 1; 2;    ; nj , (Xij;Yij)
is the sigma algebra in center j, j = 1; 2;    ; J . That is, (Xij;Yij) is a set of
all possible information generated by fX1jA; X2jA;    ; XijA; Y1j; Y2j;    ; Yijg. For
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i = 1; 2;    ; nj , dene C(zij) = (z01j; z02j;    ; z0ij)0 is the history of covariates in center
j, j = 1; 2;    ; J and Fij = (Xij;Yij) for j = 1; 2;    ; J . Let ijA be the prob-
ability that patient i in center j will receive treatment A, for i = 1; 2;    ; nj and
j = 1; 2;    ; J . We also dene similar sigma algebras when we apply a common ran-
domization for treatment assignments to all centers. In that case, for i = 1; 2;    ; n,
Xi = (X1A; X2A;    ; XiA), and Yi = (Y1; Y2;    ; Yi) are the sigma algebras gen-
erated by treatment assignments, and responses respectively with (Xi;Yi) as the
common sigma algebra. For i = 1; 2;    ; n, dene C(zi) = (z01; z02;    ; z0i)0 is the
history of covariates and Fi = (Xi;Yi). Here, iA is the probability that patient i is
getting treatment A for i = 1; 2;    ; n. In Chapter 2, response adaptive designs were
only applied to each center independently. The adaptive designs in Chapters 3 and
4, however, implemented a common randomization to all centers. In the next subsec-
tions, the denitions of adaptive designs are discussed for a common randomization
to all centers.
Restricted Randomization
When applying restricted randomization, treatment assignments of previous patients
are taken into account when choosing a treatment for a new patient. Thus, iA = 1=2
and iA = P (XiA = 1jXi 1) for i = 1; 2;    ; n.
Response-Adaptive (RA) Designs
In RA designs, treatment assignments and available responses of previous patients
are used in randomization of treatment assignments. Therefore, 1A;RA = 1=2 and
iA;RA = P [XiA = 1j(Xi 1;Yi 1)] for i = 2; 3;    ; n, where (Xi 1;Yi 1) is the sigma
algebra of treatment assignments and responses.
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Response-adaptive designs have become a desirable treatment allocation procedure in
clinical trials because they commonly lead to the assignment of more patients to the
potentially better treatment. Beginning with Zelen (1969), several authors have pro-
posed a variety of adaptive procedures for allocating treatments to patients in clinical
trials. Zelen (1969) introduced an urn based procedure commonly referred to as the
play the winner (PW) rule for comparing pairs of treatments, say A and B. In this
procedure, the rst treatment assignment to patient 1 is usually made based on the
outcome of tossing a fair coin. According to Zelen (1969), a success on a particular
treatment generates a future trial on the same treatment with a new patient; a failure
on a treatment generates a future trial on the alternate treatment. Wei and Durham
(1978) noted that the time it takes to observe the response of a patient in a clinical
trial may be much longer than the time between entry of new patients for treatment
assignment. Thus, they proposed a modication to the PW rule called the random-
ized play the winner (RPW) rule. They recommended placing an initial number of u
balls of each type in the urn. In their procedure,  balls of type A and  (    0)
balls of type B are added to the urn if the response to treatment A is a success. The
type of balls added to the urn is reversed if the response to treatment B is a success,
that is,  balls of type B and  (    0) balls of type A are added to the urn.
The randomized play the winner rule is thus usually denoted by RPW(u; ; ).
It is clear that adaptive designs based on the urn model can only be applied in clinical
trials with binary responses. If an experimenter has a target proportion of allocation
for, say treatment A in mind, the PW and RPW rules cannot be applied. As a result,
Eisele (1994) and Eisele and Woodroofe (1995) proposed a doubly adaptive biased coin
design (DBCD) which uses an allocation function g(:) to target any specied allocation
proportion  for treatment A. The design is said to be doubly adaptive because the
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procedure requires estimating the value of , the desired allocation proportion, after
each trial and also takes into account the current proportion of subjects assigned to
each treatment. In our simulation studies, we have used the allocation proportion
(P^AS; P^BS) =
p
P^AS
(
p
P^AS +
p
P^BS)
; (1.4)
proposed by Rosenberger, Stallard, Ivanova, Harper and Ricks (2001), to compute
estimates of  where P^AS and P^BS are the proportions of successes in the group of
patients assigned to treatment A and treatment B respectively. The expression (1.4)
is commonly referred to as the RSIHR allocation proportion. However, the approach
of Eisele (1994) and Eisele and Woodroofe (1995) is more complicated to achieve the
desired allocation proportion,  [see Rosenberger and Lachin (2016)]. Recently, Hu
and Zhang (2004) developed a family of allocation functions dened for all   0 by
g()(0; ) = 1; g()(1; ) = 0;
g()(; ) =
(=)
(=) + (1  )((1  )=(1  )) ; (1.5)
where  is the proportion of patients assigned to treatment A, and  is nonnegative
integer. for assigning treatments in DBCD and generalized the concept to more than
two treatments. They also studied the asymptotic properties of the proportion of pa-
tients  assigned to treatment A under certain regularity conditions. Hu et al. (2006)
then derived a lower bound for the asymptotic variance of the allocation proportions
for response-adaptive procedures under the assumption of normality. They discussed
the issue of how to choose the best adaptive design procedure for a particular experi-
ment and showed that the DBCD approach of Hu and Zhang (2004) is asymptotically
best under certain conditions. More recently, Baldi Antognini and Zagoraiou (2012)
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highlighted the importance of incorporating covariates in models for generating adap-
tive designs since the eectiveness of a treatment typically depends on the prole
of a patient. Thus, they introduced the so-called reinforced DBCD. Nevertheless,
they noted that further research is needed in analyzing the data obtained through
response-adaptive the case of generalized linear models (GLM). Additional reviews of
various types of response adaptive designs can be found in Rosenberger and Lachin
(2002), and Chow and Chang (2008).
Covariate-Adaptive (CA) Designs
If the treatment selection for a new patient is based on the previous history of pa-
tients' treatment assignments and covariate proles, as well as the covariate prole of
the new patient, then the design criterion is called the CA designs in clinical trials.
In CA designs, treatment assignments and covariates of previous patients as well as
the covariates of the current patient are employed in the selection of treatments. It
follows that iA;CA(z i) = P [XiA = 1jXi 1; C(zi 1); z i] for i = 1; 2;    ; n.
Rosenberger and Sverdlov (2008) note that \the goal of CA designs is to adaptively
balance the covariate proles of patients randomized to treatments". The objective of
balancing treatments include achieving overall balance, balance within covariate mar-
gin, and balance within stratum, which is a combination of the levels of covariates.
The advantage of achieving overall balance of treatment assignment is an increase
in the power of hypothesis testing. If pre-stratication of covariates is possible at
the initial stage of a clinical trial, then separate restricted randomization can be im-
plemented to assign treatments within each stratum to attain these balancing goals.
Such a design method is called the stratied permuted block (SPB) design. How-
ever, when the number of strata is large, then SPB design is impractical [Hu and Hu
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(2012)]. Thus, CA designs were introduced to achieve these balancing goals when
the number of strata is large. These CA designs are called minimization procedures
[Rosenberger and Sverdlov (2008)]. Moreover, many authors such as Pocock and Si-
mon (1975), Wei (1978), Hu and Hu (2012), and Lin and Su (2012) developed CA
designs to achieve the balancing of covariates to treatments in sequential clinical trials.
The equal allocation method for treatment assignments does not depend on covariate
proles. Therefore, there is a chance that under equal allocation procedures, all treat-
ment assignments to some covariate proles will be of one category, say treatment A.
When this happens, there is treatment imbalance within covariate margin or stratum.
This will then decrease the power of the test for signicance of all model parameters.
However, the overall balancing goals (nA=n! 0:5 in probability) of treatment assign-
ments can still be achieved by applying the equal allocation, where nA is the number
of patients assigned to treatment A from a total number of n patients.
The family of CA designs can be further partitioned into two sub families. The rst
family of CA designs is based on balancing treatment assignments over the covariate
proles by dening the measure of treatment imbalances. For instance, Pocock and
Simon (1975) established a measure of marginal treatment imbalances that can be
constructed by using dierences between the number of treatments within the levels
of covariates and appropriate weights. Hu and Hu (2012) developed a function for
the measure of imbalance that includes three types of treatment imbalances: overall,
marginal, and within stratum. Lin and Su (2012) developed a measure of treatment
imbalance with empirical cumulative distribution functions by using observed covari-
ates. Then, the minimization method can be applied to minimize these measures
of treatment imbalances to achieve treatment balancing goals. In the minimization
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method, when a new patient becomes available for treatment assignment, the selec-
tion probability p is chosen in such a way that there is a higher chance of assigning
the treatment that will minimize the measure of treatment imbalances over covariate
proles. Moreover, an experimenter will decide on a value greater than 1/2 and less
than or equal to one to assign to the selection probability p [see Chapter 9 of Rosen-
berger and Lachin (2016)]. In fact, if the experimenter picks the higher chance to be
equal to one, then the allocation becomes deterministic.
Covariate-Adjusted Response-Adaptive (CARA) Designs
In CARA designs, the information on treatment assignments, covariates, and re-
sponses of previous patients as well as the covariates of the current patient are uti-
lized in the new patient's treatment assignment. Thus, iA;CARA(z i) = P [XiA =
1jFi 1; C(zi 1); z i] for i = 1; 2;    ; n, where Fi 1 = (Xi 1;Yi 1).
In recent years, clinical trials are mostly conducted in ve dierent phases namely,
phase 0 to phase IV. Also, a large number of subjects participate in phase III clini-
cal trials. Thus, ethicists are consulted by a clinical trial research team to maintain
human ethical standards [see Rosenberger, Vidyashankar and Agarwal (2001)]. High
standard of ethics imply that more patients have to be treated by the best treatment.
Response-adaptive designs are known to be eective in assigning more patients to the
best treatment.
Consider the multi-center clinical trial for Stroke Prevention in Atrial Fibrillation
Study [see Hart et al. (2003), Stroke Prevention in Atrial Fibrillation Investigators
(1990)]. According to Hu et al. (2015), \Had the researchers ignored the factor of
patients anticoagulation status, which can be used as a covariate in the statistical
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model, their results would have produced a misleading conclusion that aspirin was
generally more eective than placebo in preventing the occurrence of stroke". Thus,
either aspirin or placebo is the globally best treatment to reduce the number of strokes
in patients having atrial brillation. That is, aspirin is a better treatment only for a
subgroup of patients and this clinical trial is an evidence for existence of drug by drug
interactions. In fact, researchers have been exploring the invention of personalized
medicine due to increasing availability of biomarkers and the observed heterogeneity
of patients' responses to treatment [see Sverdlov (2016)]. Therefore, how does covari-
ates in randomization of treatment assignments help to achieve objective 2 in (1.1)?
CARA design has been shown to be a method to attain this objective [Hu (2012)].
More details about CARA designs can be found in Rosenberger, Vidyashankar and
Agarwal (2001), Zhang et al. (2007), and Hu et al. (2015).
Rosenberger, Vidyashankar and Agarwal (2001) considered the application of CARA
designs based on a logit model. Zhang et al. (2007) extended the CARA designs to
more than two treatments under the framework of a generalized linear model and dis-
cussed a detailed formulation of the design under linear and logistic regression models.
But they considered separate models for each treatment while applying CARA de-
sign to select treatment assignments. Recently, Zhu (2015) noticed a drawback of
the treatment assignment procedure of Zhang et al. (2007). Zhu (2015) notes that
\it assumes that there are no common parameters for the two treatments of interest,
thus estimating every parameter based on the data from just one treatment, which
excludes many commonly used models". The model of Rosenberger, Vidyashankar
and Agarwal (2001) has been implemented user-friendly statistical software, RStudio.
Here, we will investigate the large sample behavior of the Maximum Likelihood Es-
timate (MLE) of model parameters in the model of Rosenberger, Vidyashankar and
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Agarwal (2001) for CARA designs.
According to Hu (2012), \covariate information plays an important role in the design
and analysis of clinical trials to develop personalized medicine". In fact, covariate
information is used in the randomization of CA and CARA designs. A pre-selected
objective of CA designs is achieving statistical eciency; whereas achieving participat-
ing patients' ethics is the pre-selected objective of CARA designs. Achieving eciency
and ethics goals may be stand alone objective in these adaptive designs, however, in
recent years, researchers have been interested in how to incorporate achieving both
eciency and ethics aims in a design. For example, Response-Adaptive Covariate-
Adjusted (RACA) designs have incorporated components of eciency and ethics in a
design. This design is described in the next section.
Response-Adaptive Covariate-Adjusted (RACA) Designs
Response-Adaptive Covariate-Adjusted (RACA) designs were introduced by Ning and
Huang (2010). In RACA design, the information on treatment assignments, covari-
ates, and available responses of previous patients as well as the covariates of the
current patient are used in the new patient's treatment assignment [Ning and Huang
(2010)], however noted that the mechanism of CARA and RACA designs are com-
pletely dierent. To be specic the probability of assigning a new patient to treatment
A is
iA;RACA(z i) = P [XiA = 1jFi 1; C(zi 1); z i]
=
[iA;RA]
1 [iA;CA]
2
[iA;RA]1 [iA;CA]2 + [1  iA;RA]1 [1  iA;CA]2 (1.6)
where iA;RA = P [XiA = 1j(Xi 1;Yi 1)], and iA;CA(z i) = P [XiA = 1jXi 1; C(zi 1); z i]
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for i = 2; 3;    ; n, 1 and 2 are the tuning parameters. It is clear that if 1 = 0 and
2 = 1, we get the pure CA design; if 1 = 1 and 2 = 0, we get the pure RA design.
Thus, RACA designs are the combination of RA and CA designs. Also, the measures
of eciency and ethics can be controlled by the tuning parameters in RACA designs
[see Lin et al. (2016)]. A dierence of CARA whereas an initial model is required
for its application, an initial model is not needed to apply RACA designs. According
to Yuan and Liu (2011), when we incorporate CA design into a group sequential RA
design, the resulting design combines the advantages of CA and RA design.
Response-adaptive designs create more severe treatment imbalances compared to
equal allocation over covariate proles. However, the focus of RACA designs is to
achieve simultaneously objective 1 and objective 2 in (1.1). That is, measures of
eciency and ethics are accounted in RACA designs. In fact, recent research have
focused on achieving eciency and ethics in a design. For example Hu et al. (2015)
developed a unied family of CARA designs using the components of eciency and
ethics in a design.
1.2 Statistical Models
It is well known that physical, psychological, and genetic factors can contribute to
dierences between patients in a clinical trial. Human beings are dierent among
others with respect to several factors such as physical, psychological, and genetic
factors. Thus, one can expect patient population to be heterogeneous. Therefore,
statistical modelling is required to identify the eect of treatments on the response by
including these heterogeneous factors, which are known as covariates. In what follows,
we will discuss some of these candidate models, which can be used in the analysis of
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a given data. The models are Generalized Linear Models, and Generalized Linear
Mixed Eect Models.
1.2.1 Generalized Linear Models (GLMs)
The GLMs have been implemented in various disciplines such as agriculture, eco-
nomics, engineering, medicine, and social sciences [Lindsey (1997)]. These class of
models were rst introduced by Nelder and Wedderburn (1972). Moreover, GLMs
can be seen as an extension of classical linear models [McCullagh and Nelder (1983)].
Components of GLMs
A GLM has three components, namely, the probability distribution, the linear predic-
tor, and the link function [McCullagh and Nelder (1983)]. We provide a description
of these components only for binary responses, which are success or failure. Dene,
the response Yi and treatment assignment XiA of patient i for i = 1; 2;    ; n by
Yi =
8>>>><>>>>:
1 if treatment is
a success,
0 otherwise,
and XiA =
8>>>><>>>>:
1 if patient i is assigned
to treatment A,
0 otherwise.
(1.7)
Let, z0i = (zi1;    ; zip) be the p dimensional vector of observed covariates of patient
i. We note that each component of zi is either 0 or 1, for i = 1; 2;    ; n.
Following McCullagh and Nelder (1989) it is common to dene a generalized linear
model, in general, as
E(YijxiA; zi) = g(; xiA; zi); i = 1; 2;    ; n: (1.8)
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Let i = E(YijxiA; zi). We note that the GLM in (1.8) is similar to (1.3) without
center eects. In this thesis, we consider the response to be binary. Therefore, we
have
E(YijxiA; zi) = P (Yi = 1jxiA; zi):
Our purpose is to develop the relationship between the probability of the response,
, the treatment assignment and covariates of a patient, and treatment by covariate
interactions w0i = (xiA; 1; zi; xiAz
0
i). We now describe the three components of a GLM.
1. The probability distribution of Y
When we apply equal allocation for treatment assignments, the responses are
independent. These responses are however not identically distributed because
the distribution of Yi depends on wi, where w
0
i = (xiA; 1; z
0
i; xiAz
0
i). Suppose
that conditional on wi, the binary response Yi follows the bernoulli distribution
with probability mass function
P (Yi = yijwi) = yii (1  i)(1 yi); for yi = 0; 1; (1.9)
where i = E(YijxiA; zi). Now when an adaptive design is applied to select
treatment assignments, it creates dependency among responses because the
treatment assignment will depend on accumulating data. However, the dis-
tribution assumption in (1.9) is still valid when adaptive designs are used as the
treatment selection criteria.
2. The linear predictor
We will assume that  is inuenced through a linear combination of treatment
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assignments and covariates given by
i = w
0
i;
where  is a vector of model parameters including the main eect of treatments.
3. Link function, 	
To examine the relationship between  and , we need a function to construct
the relationship. It is clear that,  takes values between 0 and 1, whereas,  can
take values between  1 and 1. The functions which dene the relationship
between  and  are called link functions in GLMs. In general,  and  are
connected through a link function
	(i) = i:
Some candidate link functions are
(i) the logit function
	1() = ln[=(1  )];
(ii) the probit function
	2() = 
 1();
(iii) the cauchit function
	3() = tan
h
  
2
i
;
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(iv) the complementary log-log function
	4() = ln[  ln(1  )]:
1.2.2 Generalized Linear Mixed Eect Models (GLMMs)
Generalized linear mixed models are very popular statistical models which have been
used extensively in many areas of applications such as biomedical, clinical trials
[Agresti and Hartzel (2000); Yaseri et al. (2014)], social science and agricultural sci-
ence. A useful discussion on the theories and applications of GLMM can be found in,
for instance Jiang (2007) and McCulloch, Searle and Neuhaus (2008).
When clinical trials are conducted in multiple centers, there is a possibility that center
eects might inuence the response. In fact, some unobservable causes may also aect
responses of patients. For example, according to Kahan (2014), some possible latent
eects are
(i) eect of variation in surgeons' skill between centers
(ii) eect of dierences in guidelines of centers
(iii) these multiple centers might be selected from dierent countries.
It is clear that under equal allocation criterion for treatment assignment, responses
of patients within a center might be correlated; but responses of patients between
centers are independent. However, we can assume that conditional on center eect,
responses of patients within a center are independent [Jiang (2007)]. Since J centers
in the experiment are randomly selected from a large number of medical centers, we
will assume that center eects are random and these center eects are heterogeneous
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between centers. On the other hand, the xed eects of covariates are common across
centers. Thus, the GLMM approach we have developed in this thesis will be used to
account for three features: (i) within center correlation, (ii) between center hetero-
geneity, and (iii) common xed eects across centers [Tuerlinckx et al. (2006)]. In
what follows, we will assume that these center eects follow a known distribution.
1.3 Statistical inference
In a clinical trial, treatment comparisons include the following: (i) nding the best
dosage level of a drug for a group of patients who have certain characteristics or co-
variates, (ii) comparing a new drug with existing drugs for a disease. Also, an ecient
treatment comparison through hypothesis testing is important for future patients. In
general, an experimenter may claim that a new treatment is more eective than an
existing treatment. Now, if there is no interaction between treatment and covariates,
the experimenter may test signicance for overall eect of treatment A compared to
treatment B through the hypothesis,
H0 : A0 = 0 HA : A0 > 0; (1.10)
where A0 is the true eect of the treatment A (the new treatment) compared to
treatment B (an existing treatment). Suppose the experimenter decides to reject H0
when, in fact, H0 is true. Then, though the new treatment does not lead to any
improvement in the responses of patients compared to the existing treatment, the
experimenter will recommend the new treatment. This type of error is called Type I
error. It is important to verify that hypothesis testing procedures are able to control
the Type I error. Thus, we will examine the size of the test through simulation studies
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in Chapter 4.
Concerning the power of test, there exist three dierent methods, (i) exact method,
(ii) approximation method, and (iii) simulation method, commonly applied for power
analysis in statistical models and tests [Castelloe (2000)]. Castelloe (2000) notes that
there is no standard procedure for power analysis in Generalized Linear Models. An
approximation method for power analysis computation of logistic regression was rst
introduced by Whittemore (1981). However, this approach is only suitable for binary
responses with rare events such as disease or death and covariates that are discrete
or continuous. These covariates were also assumed to have a joint probability dis-
tribution function. Later, Self and Mauritsen (1988) developed an approximation
procedure to power analysis based on score tests for GLMs. They implemented their
approach to categorical covariates with a nite number of distinct covariate congu-
rations. Later, Self et al. (1992) established a tool for power computation based on
the likelihood ratio test. They compared their method with the method of Self and
Mauritsen (1988) through simulation studies. Shieh (2000) carried out a simulation
study to compare the method of Whittemore (1981) and Self et al. (1992) with various
combination of response probabilities and covariate distribution in logistic regression
models. Later, Shieh (2005) proposed a method for power computation based on
Wald statistic. In fact, his/her method accommodates multiple parameters, and the
exibility of covariates congurations within the framework of GLMs. Lyles et al.
(2007) developed a method for estimating conditional power for binary, ordinal, or
count responses in GLMs.
Recently, Yi and Wang (2011) introduced the generalized score statistic method which
is an extension of Rao's score test to response-adaptive designs. They demonstrated
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that the generalized score statistic method performs well compared to the score test
when applying adaptive design as the design criteria. We observe that the design cri-
teria inuences the power of chi-squared tests through the non-centrality parameter
[see Hu and Rosenberger (2003)]. They identied three major inuence factors: (i) the
target allocation proportion, (ii) the randomization bias from target proportion, and
(iii) the variance of randomization from target proportion. Yi and Wang (2009) ex-
amined the performance of response-adaptive designs for the assignments of patients
to the best treatment and the power of the statistical test using a variance-penalized
criterion. Implementing the transition probability procedure of a Markov chain, Yi
(2013) established a method to compute the exact statistical power for the general
class of response-adaptive designs. According to Chow and Chang (2008), a major or
signicant adaptation leads to the moving target population rather than the xed tar-
get population. An eective statistical inference can be conducted considering these
strategies: (i) sample size adjustment at interim, (ii) sample size allocation to treat-
ments, (iii) delete, add, or change treatment arms, and (iv) change in study endpoints.
Recently, Ma et al. (2015) established a theoretical foundation for hypothesis testing
for parameters in linear models under a large class of CA designs, which includes
Pocock and Simon (1975) marginal method and stratied permuted block design.
Also, they used the ordinary least squares method to estimate their model parame-
ters. We will however develop a theoretical foundation for hypothesis testing when
responses are binary, and the design criteria are CARA designs. Furthermore, we
will apply the maximum likelihood method to estimate the parameters in the logit
model. The objectives of CA designs are to adaptively balance the covariate proles
of patients randomized to treatments. As a result, the power of the hypothesis testing
is maximized. On the other hand, the objectives of CARA designs are to minimize
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the assignments of patients to inferior treatment. Therefore, the objectives of these
two designs are completely dierent. That is, CA designs are less ethical than CARA
designs but CA designs are more ecient than CARA designs. In fact, CA designs
are more ecient than equal allocations [see Ma et al. (2015)].
Although Ma et al. (2015) used all the important covariates at the design stage, they
dropped some covariate information in the nal statistical inference. This will however
lead to estimators of parameters that are generally inconsistent and biased. This will
also aect the derivation for the distribution of the test statistic.
1.4 Motivation and contribution of this thesis
1.4.1 Motivation of this thesis
According to Hu et al. (2006), properties of the statistical methods under RA de-
signs are well established under the assumption of a simple homogeneous parametric
structure [see Wei (1978); Ivanova (2003); Eisele (1994); Hu and Zhang (2004); Yi
and Wang (2007); Yi and Wang (2011); Rosenberger et al. (1997)]. The diversity
of patients' characteristics were not considered in the investigation of RA designs.
Rosenberger and Hu (2002) provided some conditions for the asymptotic normality
of regression parameters in Generalized Linear Models (GLMs) that includes covari-
ates of patients when sequential designs are applied to treatment assignments. When
we add center eects in GLM, we have two modelling approaches, namely, GLM
with xed grouping eects and Generalized Linear Mixed Eect Model (GLMM) [see
Agresti and Hartzel (2000) and Brostrom and Holmberg (2001)]. In this thesis, we
examine the performance of RA randomizations when a Generalized Linear Mixed
Eect Model (GLMM) is the parametric model in multi-center clinical trials.
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Yi and Wang (2007) provided conditions for consistency and asymptotic normality
of ML estimators for a class of adaptive designs under the assumption that only
treatment inuences the response. Rosenberger, Vidyashankar and Agarwal (2001)
demonstrated that CARA designs reduces the number of patients assigned to inferior
treatments through simulation studies. However, the large sample behavior of regres-
sion parameters of the model in Rosenberger, Vidyashankar and Agarwal (2001) was
not discussed in the literature for CARA designs [see Basak et al. (2009)]. Thus,
one of the objectives of this thesis is to establish the conditions for consistency and
asymptotic normality of ML estimators for CARA designs.
Rosenberger, Vidyashankar and Agarwal (2001) discussed the most natural mapping,
dened in x 3.7, with model based odds ratio for reducing the number of patients to
inferior treatments. In fact, we can eciently minimize the number of patients to in-
ferior treatments if the initial model for applying CARA design is correctly specied.
In other words, the assignment of patients to better treatments might be inecient
if an initial model is misspecied. However, when we apply the RA designs using
proportions, the initial model is not required. In what follows, we will investigate the
eciency and ethics between RA and CARA designs.
Even though data collected from RA designs are dependent among responses, Yi and
Wang (2011) justied that Wald, score, and the likelihood ratio tests can be used
when the sample size is large. Moreover, they introduced the generalized score statis-
tic for RA designs and concluded that the performance of Wald test is better than
the score test, the generalized score test, and the likelihood ratio test. In fact, this
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result motivated us to discuss the Wald test for adaptive designs considering the het-
erogeneity of patients' characteristics in the logit model.
Covariate-adaptive designs are usually applied to quickly achieve objective 1 in (1.1).
Furthermore, RA designs generate more severe imbalances of covariates over treat-
ment arms when compared to equal allocation [Ning and Huang (2010)]. Hence, Ning
and Huang (2010) introduced the Response-Adaptive Covariate-Adjusted (RACA)
designs to achieve objective 1 and objective 2 in (1.1) simultaneously. Now, if
treatment by covariate interactions exist, then CARA designs will reduce the number
of patients assigned to inferior treatments. However, Ning and Huang (2010) dis-
cussed that \the identication of such interaction terms in regression models is not
feasible unless the sample size is large". This observation motivated us to compare
the performance of CARA designs with RA designs through simulation studies.
Hu and Rosenberger (2003) explored the relationship between the non-centrality pa-
rameter of the usual chi-square test for binary responses and the design's quantities:
the target allocation proportion, the bias of the randomization procedure from that
target, and the variability induced by the randomization process. However, they de-
rived an expression for the non-centrality parameter under the assumption of a simple
homogeneous parametric structure. These results motivated us to consider deriving
the non-centrality parameter when we relax the assumption of simple uniform para-
metric structure and prove the relationship between the non-centrality parameter and
target allocation proportion when a covariate is in the logit model.
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1.4.2 Contribution of this thesis
In this section, we discuss our contribution to the literature through this thesis. In
Chapter 2, we propose an approach to investigate the large sample theory of regression
parameters of Generalized Linear Mixed Models (GLMMs) with sequential designs via
the inuence function method for familial data that was developed by Zhang and Oyet
(2014). The performance of RA designs was investigated for GLMMs. Moreover, the
inuence function of ML estimates was derived and used to obtain a closed form ex-
pression of the asymptotic covariance of ML estimates, which does not currently exist
in the literature. A new searching method for estimating the model parameters is
introduced based on the inuence function method. Also, we veried that this new
iteration method works better than the Hessian matrix searching method through
simulation studies and application to real data. The main results of Chapter 2 are
outlined in a recent paper by Selvaratnam, Oyet, Yi and Gadag (2017).
In Chapter 3, we discuss the logit model for a general class of adaptive designs. The
consistency and asymptotic normality of ML estimators of regression parameters of
logit model was examined for adaptive designs. We reduced the strong regularity
assumption that Fisher information and observed Fisher information matrices are
positive denite matrices within a neighborhood that is close to vector of true param-
eters to a weaker assumption. This weak assumption is that the Fisher information
matrix is positive dene matrix at the vector of true parameters. We consider the
odds-ratio-based limiting allocation that was introduced by Basak et al. (2009). We
apply the Doubly adaptive Biased Coin Design (DBCD) to target this limiting al-
location. Furthermore, the performance of this RA randomization is compared with
CARA designs and equal allocation by simulation studies.
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In Chapter 4, we investigate the power computation methods for a general class of
adaptive designs. We examine the asymptotic distribution of the Wald test statistic in
hypothesis testing under null and alternative hypothesis for adaptive designs consider-
ing the logit model as a true model. We investigate the performance of three designs:
the RA design, the CARA design, and equal allocation. In this investigation, we
examine the quantities: the number of patients assigned to the inferior treatment, the
design variability, statistical power for testing hypotheses, and Type I error rates. We
examine the non-centrality parameter of the Wald test for binary responses with the
inclusion of heterogeneous patients' characteristic in a logit model. We proved that
this non-centrality parameter is a function of the design proportions. Furthermore,
we demonstrated that this function is concave when we assume only one covariate in
the logit model.
Chapter 2
Estimation of a Generalized Linear
Mixed Model for
Response-Adaptive Designs in
Multi-Center Clinical Trials
2.1 Introduction
The objective of comparing the eectiveness of two treatments in a clinical trial is
not only gathering information about the relative eectiveness of the treatments but
also assigning treatments to patients in a way that consider the wellbeing of patients;
that is objective 2 in (1.1). The response-adaptive designs are generally discussed
in the literature to achieve this objective in a clinical trial assuming a simple ho-
mogeneous parametric structure. In this chapter, we examine the performance of
response-adaptive designs when we assume the generalized linear mixed eect model
(GLMM) is an ideal model.
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The construction of likelihood functions under GLMM has largely assumed that co-
variates are xed. However, generating treatment assignments through adaptive de-
signs create dependency among responses. Consequently, we follow the approach of
Rosenberger et al. (1997), Hu et al. (2006), and Yi and Wang (2007) to construct the
likelihood function for GLMM with response-adaptive randomization by using the
idea of likelihood function for sequential decision process. One diculty commonly
associated with using GLMMs is the problem of obtaining closed form expressions for
the asymptotic variance of MLEs of the model parameters because the likelihood func-
tion contains integrals which cannot be solved analytically. Thus, asymptotic results
in the literature have been based on the inverse of the Hessian matrix obtained from
the likelihood function. In this chapter, we avoid the complications introduced by
the integrals that cannot be solved analytically by using a Gauss-Hermite quadrature
method to approximate the integrals in the likelihood function. This novel approach
then allows us to exploit inuence function techniques, as in Zhang and Oyet (2014),
to establish the asymptotic properties of consistency and normality and to derive a
closed form expression for the asymptotic covariance matrix of the MLEs. These re-
sults are outlined in Theorem 2.3.1 of x 2.3.
In x 2.2, we introduce the likelihood function for GLMM with response-adaptive ran-
domization and apply the Gauss-Hermite quadrature to obtain the MLEs of the model
parameters. The Gauss-Hermite quadrature has also been used by other authors to
approximate integrals in generalized linear mixed models. See for instance Agresti
and Hartzel (2000), Fahrmeir and Tutz (2001), Brostrom and Holmberg (2001), and
Fortin (2013). We derive the inuence function of the MLEs in x 2.3 and use this
result to discuss the consistency and asymptotic normality of the MLEs. The results
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of a simulation study and an application to real data are discussed in x 2.4 and x 2.5
respectively. We conclude this chapter with some remarks in x 2.6.
2.2 The Model and Parameter Estimation
Suppose that patients are recruited sequentially into a center and each patient is
treated with one and only one of two treatments A and B. Suppose the number of
patients within center j, nj , is assumed to be xed. Also, responses and treatment
assignments of all n patients are dened in (1.2). Furthermore, let Xij = (1; XijA)
0 as
the covariate associated with the binary response Yij. In what follows, we will assume
that the response Yij is generated from a GLMM given by
logit[P (Yij = 1juj; xijA)] = x0ij + uj (2.1)
where  = (0; A)
0 and the random center eect uj, j = 1; 2;    ; J , are independent
normal random variables with mean zero and common variance 2.
For i  2, let ijA = P [XijA = 1j(x1jA; y1j);    ; (x(i 1)jA; y(i 1)j)] and ijB =
1   ijA; 1  j  J . In response-adaptive designs, the random allocation rule
j = fij; i = 1; 2;   njg typically consists of a sequence of vector of probabili-
ties, where ij = (ijA; ijB). It is common to pre-specify the value of the allocation
probability for the rst patient in center j, j = 1; 2;    ; J , 1jA = P (X1jA = 1)
to, say a value of 1/2. Clearly, the fact that each ij, i  2 depends on previous
treatment assignments and responses induce some dependency among the collected
data. Thus, following Yi and Wang (2007), the unconditional likelihood function for
34
f(yij; xijA); j = 1; 2;    ; J and i = 1; 2;    ; njg can be written as
LR() =
JY
j=1
Z 1
 1
 njY
i=1


xijA
ijA 
(1 xijA)
ijB P (Yij = yij juj ; xijA)

1p
2
exp( u2j=22)

duj
= h(~)
JY
j=1
Z 1
 1
 njY
i=1

1 + exp( x0ij   uj)
 yij 
1 + exp(x0ij + uj)
 (1 yij)
1p
2
exp( u2j=22)

duj ; (2.2)
where h(~) =
JY
j=1
(1=
p
)
njY
i=1

xijA
ijA 
(1 xijA)
ijB and 
0 = (0; ). In the special case of equal allo-
cation, h(~) / (1=2)n.
Next, we let r = 1 if a patient receives treatment A and r = 0 otherwise and apply
the transformation uj =
ujp
2
to (2.2), to obtain
LR() = h(~)
JY
j=1
Z 1
 1
 1Y
r=0
h
1 + exp( 0   Ar  
p
2uj )
i njrS
h
1 + exp(0 + Ar +
p
2uj )
i njrF 
exp( [uj ]2)

duj : (2.3)
In (2.3), njrS and n

jrF are the number of successes and failures respectively, in center
j under treatment r. Given yj = (y1j; y2j;    ; ynjj)0, the observed vector of responses
from center j, the log-likelihood function of  can be written as
lR() = lnh(~) +
JX
j=1
ln
Z 1
 1
fyj (u

j ;)e
 [uj ]2duj ;
where fyj (u
;) =
1Y
r=0

1 + exp( 0Vr)
 njrS 1 + exp(0Vr) njrF with V0r = (1; r;p2u).
We note that the integral in lR() cannot be solved analytically. Therefore, we have
used the Gauss-Hermite quadrature method to approximate the integral in the fol-
lowing way. Let d be the number of sample points to be used in the approximation
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and sh the roots of the Hermite polynomial Qd(s) (h = 1; 2;    ; d) with associated
weights wh. Then, by applying the Gauss-Hermite approximation to the integral in
the log-likelihood function lR() we have
lR()  lnh(~) +
JX
j=1
ln
"
dX
h=1
whfyj (sh;)
#
: (2.4)
By Theorem 5.1.9 of Brass and Petras (2011), for each j; j = 1;    ; J , the Gauss-
Hermite approximation converges to the exact integral as d !1.
In our simulation studies and in our application to real data, the optimx function in R
software was applied to solve the maximum likelihood estimating equation
@lR()
@
= 0,
where
@lR()
@

JX
j=1
8<:
"
dX
h=1
whfyj (sh;)
# 1 "
dX
h=1
wh
@fyj (sh;)
@
#9=;; (2.5)
with
@fyj (u
;)
@
= fyj (u
;)
@ ln fyj (u
;)
@
. Now,
ln fyj (u
;) =  
1X
r=0
fnjrS ln[1 + exp( 0Vr)] + njrF ln[1 + exp(0Vr)]g;
@ ln fyj (u
;)
@
=  
1X
r=0

njrS
exp( 0Vr)
[1 + exp( 0Vr)]
( 1)Vr + njrF
exp(0Vr)
[1 + exp(0Vr)]
Vr

=
1X
r=0

njrS
1
[1 + exp(0Vr)]
Vr   njrF
1
[1 + exp( 0Vr)]
Vr

=
1X
r=0

njrS [1 + exp(
0Vr)] 1Vr   njrF [1 + exp( 0Vr)] 1Vr
	
: (2.6)
The inputs to the optimx function in R were the log-likelihood function (2.4), the
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gradient vector in (2.5) and the Hessian matrix
@2lR()
@@0
, given by
@2lR()
@@0

JX
j=1
("
dX
h=1
whfyj (sh;)
# 1 "
dX
h=1
wh
@2fyj (sh;)
@@0
#
 
"
dX
h=1
whfyj (sh;)
# 2 "
dX
h=1
wh
@fyj (sh;)
@
#"
dX
h=1
wh
@fyj (sh;)
@0
#)
; (2.7)
where
@fyj (u
;)
@0
=

@fyj (u
;)
@
0
@2fyj (u
;)
@@0
=
@ ln fyj (u
;)
@
@fyj (u
;)
@0
+
@2 ln fyj (u
;)
@@0
fyj (u
;);
and
@2 ln fyj (u
;)
@@0
=  
1X
r=0

njrS exp(
0Vr)[1 + exp(0Vr)] 2 + njrF exp( 0Vr)[1 + exp( 0Vr)] 2

VrV
0
r:
2.3 Asymptotic Properties
We mentioned earlier that the presence of integrals, which are functions of the un-
known parameter vector , in the likelihood function for GLMMs has limited the
ability of previous authors to verify conditions that are necessary for an appropriate
central limit theorem to be valid. In this section, we avoid this diculty by rst
deriving the inuence function of the MLEs and then using the result to obtain the
asymptotic properties of the MLEs. Zhang and Oyet (2014) applied a similar approach
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to derive the asymptotic properties of the generalized quasi likelihood estimators of
the parameters of a branching process model. In statistics, the inuence function is
the eect on an estimator of changing one point of the sample. The inuence func-
tion of an estimate also indicates the sensitivity of the estimate to the observations
Shen (1995). We note that in general, the number of patients within each center
may not be equal. However, we will assume that the number of patients in each of
the J centers is xed but the number of centers J can be increased as many as possible.
Now, for xed i; i = 1; 2;    ; n0 where n0 = min(n1; n2;    ; nJ), let Y1;Y2;    ;YJ
be a sequence of independent and identically distributed random vectors with joint
distribution function F (t); t = (t1; t2;    ; tn0)0. Dene the empirical distribution
function of the observed responses y1;y2;    ;yJ as
F J (t) =
1
J
JX
j=1
yj(t);
where yj(t) is the indicator function
yj(t) =
8><>: 1 if y1j  t1; y2j  t2;    ; yn

0j
 tn0 ;
0 otherwise.
For an arbitrary distribution function G and   0, dene F  = (1 )F +G to be
the -contaminated distribution function of F . Then, using (2.5), the ML estimating
equation
@lR()
@
can be written as
L(y;; F J ) =
@lR()
@
=
Z " dX
h=1
whfy(sh;(F

J ))
# 1 "
dX
h=1
whHy(sh;(F

J ))
#
dF J (y) = 0;
(2.8)
where Hy(sh;) =
@fy(sh;)
@
. That is, (F J ) = ^ is a solution to (2.8). To simplify
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notations, we let
Ay =
"
dX
h=1
whfy(sh;(F

 ))
# 1
and; By =
"
dX
h=1
whHy(sh;(F

 ))
#
: (2.9)
Then, with
A0y = Ayj=0 and B0y = Byj=0; (2.10)
we have that
L(y;; F ) =
Z " dX
h=1
whfy(sh;(F
))
# 1 "
dX
h=1
whHy(sh;(F
))
#
dF 
=
Z
A0yB0ydF
 = 0; (2.11)
since the true value of , (F ) is also a solution to the estimating equation. By
denition, the inuence function of ^ at F  is the Ga^teaux derivative of (F  ) at
 = 0 and G = yj(y).
Now, at F  , since(2.11) we have
L(y;; F  ) =
Z " dX
h=1
whfy(sh;(F

 ))
# 1 "
dX
h=1
whHy(sh;(F

 ))
#
dF 
=
Z
AyBydF

 = 0 (2.12)
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Therefore, the partial derivative of L(y;; F  ) with respect to  is given by
@L(y;; F  )
@
=
@
@
Z
AyBydF

 (y)
=
Z
@AyBydF

 (y)
@
=
Z
@AyBydF

 (y)
0(F  )
@(F  )
@
=
Z 
@Ay
@0(F  )
BydF

 (y) +Ay
@By
@0(F  )
dF  (y) +AyBy
@dF  (y)
@0(F  )

@(F  )
@
=
Z 
@Ay
@0(F  )
By

@(F  )
@
dF  (y) +
Z 
Ay
@By
@0(F  )

@(F  )
@
dF  (y) +
Z
[AyBy] d
@F  (y)
@
=
Z
@Ay
@0(F  )
By
@(F  )
@
dF  +
Z
Ay
@By
@0(F  )
@(F  )
@
dF  +
Z
AyBy(dG
   dF );
It follows that at  = 0, we have
@L(y;; F  )
@

=0
=
Z 
@A0y
@0(F )
B0y

I((G))dF  +
Z 
A0y
@B0y
@0(F )

I((G))dF  +
Z
A0yB0y(dG
   dF )
=
Z 
@A0y
@0(F )
B0y

I((G))dF  +
Z 
A0y
@B0y
@0(F )

I((G))dF  +
Z
A0yB0ydG
;
where @A0y
@0(F )
=
@Ay
@0(F  )

=0
, @B0y
@0(F )
=
@By
@0(F  )

=0
, and I((G)) = @(F

 )
@

=0
. Now to obtain
the inuence function for a given distribution function G and
I((G)) =  
Z 
B0y
@A0y
@0(F )
+A0y
@B0y
@0(F )

dF 
 1 Z
A0yB0y dG


;
= EG [ C 1B0yA0y] (2.13)
where C =
Z 
B0y
@A0y
@0(F )
+A0y
@B0y
@0(F )

dF . From (2.11) and (2.13), it is easy to see
that at G = F  we have, I((F )) = EF [ C 1B0yA0y] = 0. We also have that, at
G = yj(y) the inuence function of  at F
 becomes IF (y;; F ) =  C 1B0yA0y. In
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order to derive the asymptotic properties of the MLE, (F J ) of , we rst use the
Taylor series expansion to obtain the rst order approximation of (F  ), as
(F  ) = (F

 )j=0 +
@(F  )
@

=0
+   
= (F ) + EG [IF (y;; F )] +    ;
for any  and G. In particular, at  = 1 and G = F J we have
(F J )  (F ) 
1
J
JX
j=1
IF (yj;; F
);
which can also be written as
p
J((F J )  (F )) 
1p
J
JX
j=1
IF (yj;; F
):
Therefore, by the strong law of large numbers
1
J
JX
j=1
IF (yj ;; F
) a:s  ! 0, since
EF  [IF (y;; F
)] = 0. Furthermore, 1p
J
JX
j=1
IF (yj ;; F
) d ! N(0;), by the central
limit theorem where  = EF  [IF (y;; F
)IF (y;; F )0]. These results are summa-
rized in the following theorem.
Theorem 2.3.1. Suppose nj = n

0 for j = 1; 2;    ; J and Y1;Y2;    ;YJ be a se-
quence of independent and identically distributed random variables with distribution
function F (y). Let F J (y) be the empirical distribution function of the observed re-
sponses y1;y2;    ;yJ . Then, using the Gauss-Hermite approximation dened in (2.4)
such that d !1 where d is the number of sample points in the Gauss-Hermite ap-
proximation, we have that
(a) the inuence function of  at F  is IF (y;; F ) =  C 1B0yA0y,
(b) by the strong law of large numbers, (F J )
a:s ! (F ) as J !1, and
41
(c) by the central limit theorem,
p
J((F J )  (F )) d ! Nf0;g as J !1, with
 = EF  [IF (y;; F
)IF (y;; F )0].
In our simulation studies, we have used the plug-in estimate of the asymptotic covari-
ance matrix of ^ to compute an estimate of the variance of the MLE of . It can be
easily veried that the plug-in estimate is given by
V^ (^) =
1
J
EF J [IF (y;; F
)IF (y;; F )0];
=
1
J2
JX
j=1
IF (yj;; F
)IF 0(yj;; F ); (2.14)
where IF (yj;; F
) =  C 1S B0yjA0yj and
CS =
1
J
JX
j=1

B0yj
@A0yj
@0(F )
+ A0yj
@B0yj
@0(F )

: (2.15)
2.4 Simulation Studies
In this section, we examine the performance of the ML estimation procedure and the
asymptotic results we derived in (2.2) and (2.3) respectively, through simulation stud-
ies. For this purpose, we have chosen J = 25, 50, and 100 centers with n0 = n

j = 15
patients in each of the centers in order to examine the performance of the estimates
for small (J = 25), moderate (J = 50) and large (J = 100) values of J . Each data set
used in computing the parameter estimates and values of the asymptotic variances
was generated using various combinations of values of the parameters 0; A and .
The values of the parameters we considered were (a) 0 =  2; A = 3; and  = 0:8;
(b) 0 =  1; A = 4; and  = 1; and (c) 0 = 0:5; A = 1; and  = 0:8. It is clear,
from our discussions that the assignment of treatments to patients in each center will
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depend on the response-adaptive design used in the clinical trials. The choice of design
for treatment assignment will also aect the performance of the parameter estimates.
Therefore, in our simulation studies we will compare the performance of the estimates
under the completely randomized design (CRD), the RPW rule introduced by Wei
and Durham (1978), and the doubly adaptive biased coin design targeting the RSIHR
desired allocation to treatment A (Doubly).
The data generation procedure we applied starts with an initial assignment of treat-
ment A to patient 1 and treatment B to patient 2. This initial assignment automat-
ically determines the values of the covariate XijA to be x1jA = 1 and x2jA = 0. We
then used equation (2.17) to compute the conditional probability that the response
of the treatments assigned to patient i is a success given that they were treated in
center j, j xed. Suppose we denote this conditional probability by  . Then, the
response for patient i in center j was obtained by generating a Bernoulli observation
with probability of success  . In order to generate the response for the next patient
in the same center, we rst used one of the designs (CRD, RPW or Doubly) to assign
a treatment to the patient. As noted earlier, once the treatment has been assigned,
the value of the covariate XijA is known. The process of generating the ith response
and treatment assignment for a xed design was then repeated until all patients in a
given center j have been treated. The entire data generating process was repeated to
generate data for each of the 25, 50 or 100 centers.
Under CRD, patients have an equal chance of receiving either treatment A or treat-
ment B. That is, for a xed center j = 1; 2;    ; J , P (XijA) = 1=2, i = 3; 4;    ; nj .
So, to determine the treatment for the next available patient we started by generating
a Bernoulli observation with probability of success 1/2. We then assigned treatment
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Table 2.1: Proportion of patients assigned to treatment A in all centers (A) based
on RPW, CRD and Doubly procedures from 3000 simulations. Simulated means
(SM) and simulated standard errors (SSE), estimated standard errors based on the
Hessian matrix (ESE), estimated standard errors based on the inuence function
(IESE), mean squared error (MSE) and 95% coverage probability [C95%] based on
normal distribution for the MLEs of model parameters, with covariate eects 0 =  2,
A = 3,  = 0:8, J = 100 and n

0 = 15.
Design Quantity ^0 ^A ^ A
RPW SM -2.0110 3.0068 0.7914 0.6514
SSE 0.1612 0.1669 0.1034 0.0128
ESE 0.1617 0.1664 0.1047 -
IESE 0.1610 0.1649 0.1033 -
MSE 0.0523 0.0556 0.0218 -
C95% 0.9490 0.9530 0.9487 -
CRD SM -2.0043 3.0051 0.7850 0.5002
SSE 0.1430 0.1535 0.1051 0.0120
ESE 0.1423 0.1565 0.1066 -
IESE 0.1418 0.1550 0.1048 -
MSE 0.0408 0.0481 0.0227 -
C95% 0.9493 0.9523 0.9527 -
Doubly0 SM -2.0064 3.0090 0.7906 0.5876
SSE 0.1516 0.1631 0.1070 0.0120
ESE 0.1518 0.1613 0.1054 -
IESE 0.1511 0.1600 0.1042 -
MSE 0.0462 0.0527 0.0227 -
C95% 0.9483 0.9470 0.9473 -
Doubly3 SM -2.0100 3.0080 0.7880 0.6172
SSE 0.1587 0.1668 0.1048 0.0067
ESE 0.1549 0.1626 0.1046 -
IESE 0.1541 0.1612 0.1032 -
MSE 0.0494 0.0544 0.0221 -
C95% 0.9433 0.9420 0.9513 -
Doubly7 SM -2.0108 3.0086 0.7858 0.6221
SSE 0.1580 0.1650 0.1036 0.0059
ESE 0.1555 0.1630 0.1044 -
IESE 0.1547 0.1618 0.1029 -
MSE 0.0493 0.0539 0.0218 -
C95% 0.9490 0.9507 0.9520 -
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Table 2.2: Proportion of patients assigned to treatment A in all centers (A) based on
RPW, CRD and Doubly DBCD procedures from 3000 simulations. Simulated means
(SM) and simulated standard errors (SSE), estimated standard errors based on the
Hessian matrix (ESE), estimated standard errors based on the inuence function
(IESE), mean squared error (MSE) and 95% coverage probability [C95%] based on
normal distribution for the MLEs of model parameters, with covariate eects 0 = 0:5,
A = 1,  = 0:8, J = 50 and n

0 = 15.
Design Quantity ^0 ^A ^ A
RPW SM 0.4992 1.0058 0.7849 0.5615
SSE 0.1736 0.1907 0.1482 0.0280
ESE 0.1688 0.1858 0.1441 -
IESE 0.1687 0.1834 0.1409 -
MSE 0.0589 0.0710 0.0431 -
C95% 0.9450 0.9407 0.9427 -
CRD SM 0.4983 1.0027 0.7818 0.5001
SSE 0.1606 0.1807 0.1455 0.0167
ESE 0.1607 0.1807 0.1426 -
IESE 0.1610 0.1780 0.1394 -
MSE 0.0519 0.0653 0.0420 -
C95% 0.9530 0.9527 0.9433 -
Doubly0 SM 0.5007 1.004 0.7801 0.5242
SSE 0.1650 0.1816 0.1429 0.0182
ESE 0.1627 0.1813 0.1429 -
IESE 0.1630 0.1788 0.1398 -
MSE 0.0540 0.0659 0.0414 -
C95% 0.9440 0.9480 0.9470 -
Doubly3 SM 0.5018 1.006 0.7823 0.5314
SSE 0.1651 0.1775 0.1440 0.0098
ESE 0.1628 0.1790 0.1431 -
IESE 0.1632 0.1768 0.1400 -
MSE 0.0540 0.0636 0.0416 -
C95% 0.9387 0.9493 0.9457 -
Doubly7 SM 0.5022 1.005 0.7828 0.5320
SSE 0.1647 0.1795 0.1443 0.0084
ESE 0.1629 0.1787 0.1430 -
IESE 0.1634 0.1766 0.1396 -
MSE 0.0539 0.0642 0.0417 -
C95% 0.9400 0.9490 0.9450 -
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Table 2.3: Proportion of patients assigned to treatment A in all centers (A) based on
RPW, CRD and Doubly DBCD procedures from 3000 simulations. Simulated means
(SM) and simulated standard errors (SSE), estimated standard errors based on the
Hessian matrix (ESE), estimated standard errors based on the inuence function
(IESE), mean squared error (MSE) and 95% coverage probability [C95%] based on
normal distribution for the MLEs of model parameters, with covariate eects 0 =  2,
A = 3,  = 0:8, J = 25 and n

0 = 15.
Design Quantity ^0 ^A ^ A
RPW SM -2.0326 3.0291 0.7569 0.6514
SSE 0.3353 0.3478 0.2228 0.0263
ESE 0.3262 0.3375 0.2180 -
IESE 0.3194 0.3281 0.2048 -
MSE 0.2217 0.2370 0.1013 -
C95% 0.9500 0.9570 0.9710 -
CRD SM -2.0200 3.0250 0.7629 0.4997
SSE 0.2820 0.3182 0.2300 0.0244
ESE 0.2862 0.3165 0.2250 -
IESE 0.2821 0.3065 0.2097 -
MSE 0.1633 0.2027 0.1103 -
C95% 0.9520 0.9527 0.9787 -
Doubly0 SM -2.0237 3.0257 0.7617 0.5870
SSE 0.3083 0.3284 0.2278 0.0235
ESE 0.3054 0.3263 0.2205 -
IESE 0.2990 0.3144 0.2060 -
MSE 0.1905 0.2159 0.1045 -
C95% 0.9520 0.9550 0.9737 -
Doubly3 SM -2.0281 3.0292 0.7617 0.6168
SSE 0.3137 0.3304 0.2253 0.0131
ESE 0.3123 0.3293 0.2186 -
IESE 0.3060 0.3180 0.2050 -
MSE 0.1983 0.2194 0.1029 -
C95% 0.9513 0.9537 0.9680 -
Doubly7 SM -2.0315 3.0296 0.7583 0.6220
SSE 0.3163 0.3278 0.2223 0.0116
ESE 0.3136 0.3302 0.2175 -
IESE 0.3070 0.3187 0.2048 -
MSE 0.2010 0.2184 0.0999 -
C95% 0.9507 0.9570 0.9667 -
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A to the patient if the outcome was 1. In this case, xijA = 1. Alternatively, we
assigned treatment B to the patient if the outcome was 0. In this case, xijA = 0.
In order to determine the treatment allocation under DBCD targeting the RSIHR
desired allocation to treatment A (Doubly), we used available information and the
expression (1.4) proposed by Rosenberger, Stallard, Ivanova, Harper and Ricks (2001)
to compute an estimate of the desired allocation proportion  to treatment A. We
then used the estimated desired allocation proportion  to calculate the DBCD treat-
ment allocation function (1.5) for treatment A for each value of the parameter  =
0, 3 and 7, where  is the proportion of patients assigned to treatment A. In a se-
quential process, the values of  and  in (1.4) were separately updated for each center.
The results in Tables 2.1 - 2.5 show that the ML estimating procedure we outlined in
2.2 performed well by consistently estimating the model parameters. In addition to
estimating the parameters, we also computed the standard errors of the estimators in
three ways for the purpose of comparison and validating our theoretical results. First,
we computed the variance of the estimates obtained from the 3000 simulations. We
have denoted the standard errors obtained by taking the square root of the variance
computed from this method by SSE. Secondly, we used the inverse of the Hessian ma-
trix obtained at the nal stage of the maximization process to compute the standard
errors and nally, we used the plug-in estimate of variance based on the inuence
function in (2.14) to compute the standard errors. The estimates of the standard
errors shown in Tables 2.1 - 2.5 are very similar in magnitude. In the tables, the
estimated standard errors denoted by ESE are based on the inverse of the Hessian
matrix and the inuence function based estimated standard errors are denoted by
IESE. Bias is calculated by the dierence between ML estimate and true parameter.
Then, MSE is computed by the sum of squared bias and ESE. Since the values of the
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estimated standard errors from all three methods are very similar, we used the ESE
to construct 95% condence intervals for the parameters 0; A, and  based on the
assumption of normality. These results are also shown in Tables 2.1 - 2.5. In all cases,
the estimated coverage probability under the assumption of normality was found to
be approximately 95% under each of the designs we considered. There was however
some slight deviations in the coverage probability estimate for the variance ^ when J
= 25 (Table 2.3). These simulation results validate the inuence function based proof
of asymptotic normality of the parameter estimates we outlined in the section 2.3.
The values of A in Tables 2.1 - 2.5 show that the two response-adaptive designs
namely, RPW and DBCDs, consistently assigned the treatment with high probability
of success to more patients which is a morally and ethically desirable outcome. That
is, A is larger than 50% in both cases, whereas A = 50% under CRD. We had
mentioned earlier that the simulated mean squared errors for all response-adaptive
designs considered in this chapter were similar in value. Our simulation results also
show that the design variability under DBCD becomes increasingly smaller than those
under RPW and CRD as  becomes larger in magnitude. For instance, in Table 2.1,
the design variability under RPW and CRD were 0.0128 and 0.0120 respectively,
whereas, the design variability under DBCD for  = 0; 3; 7 were 0.0120, 0.0067 and
0.0059 respectively. A similar pattern can be seen in the values of the design variability
in Tables 2.2 - 2.5. These results agree with the conclusion of Hu et al. (2006) who
noted that the design variability of the allocation proportion can attain its lower bound
for larger values of . Taken together, these simulation results demonstrate that the
Gauss-Hermite quadrature method was eective in approximating the integral in the
log-likelihood function.
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Table 2.4: Proportion of patients assigned to treatment A in all centers (A) based on
RPW, CRD and Doubly DBCD procedures from 3000 simulations. Simulated means
(SM) and simulated standard errors (SSE), estimated standard errors based on the
Hessian matrix (ESE), estimated standard errors based on the inuence function
(IESE), mean squared error (MSE) and 95% coverage probability [C95%] based on
normal distribution for the MLEs of model parameters, with covariate eects 0 =  1,
A = 4,  = 1, J = 100 and n

0 = 15.
Design Quantity ^0 ^A ^ A
RPW SM -0.9977 3.9989 0.9853 0.6958
SSE 0.1569 0.2177 0.1364 0.0156
ESE 0.1586 0.2163 0.1363 -
IESE 0.1580 0.2142 0.1333 -
MSE 0.0499 0.0944 0.0374 -
C95% 0.9477 0.9530 0.9523 -
CRD SM -1.0033 4.0092 0.9902 0.4998
SSE 0.1354 0.2082 0.1288 0.0121
ESE 0.1365 0.2088 0.1261 -
IESE 0.1364 0.2069 0.1242 -
MSE 0.0371 0.0872 0.0326 -
C95% 0.9530 0.9540 0.9487 -
Doubly0 SM -1.0051 4.0099 0.9902 0.5846
SSE 0.1424 0.2094 0.1330 0.0124
ESE 0.1440 0.2106 0.1301 -
IESE 0.1436 0.2082 0.1278 -
MSE 0.0412 0.0884 0.0348 -
C95% 0.9610 0.9507 0.9420 -
Doubly3 SM -1.0049 4.0090 0.9913 0.6104
SSE 0.1453 0.2088 0.1338 0.0071
ESE 0.1460 0.2108 0.1312 -
IESE 0.1455 0.2085 0.1285 -
MSE 0.0426 0.0883 0.0352 -
C95% 0.9460 0.9533 0.9460 -
Doubly7 SM -1.0051 4.0084 0.9904 0.6140
SSE 0.1449 0.2093 0.1362 0.0064
ESE 0.1463 0.2110 0.1313 -
IESE 0.1458 0.2088 0.1288 -
MSE 0.0426 0.0886 0.0360 -
C95% 0.9523 0.9533 0.9380 -
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Table 2.5: Proportion of patients assigned to treatment A in all centers (A) based on
RPW, CRD and Doubly DBCD procedures from 3000 simulations. Simulated means
(SM) and simulated standard errors (SSE), estimated standard errors based on the
Hessian matrix (ESE), estimated standard errors based on the inuence function
(IESE), mean squared error (MSE) and 95% coverage probability [C95%] based on
normal distribution for the MLEs of model parameters, with covariate eects 0 = 0:5,
A = 1,  = 0:8, J = 100 and n

0 = 20.
Design Quantity ^0 ^A ^ A
RPW SM 0.5023 0.9997 0.7922 0.5717
SSE 0.1124 0.1151 0.0895 0.0190
ESE 0.1116 0.1136 0.0901 -
IESE 0.1117 0.1130 0.0894 -
MSE 0.0251 0.0261 0.0162 -
C95% 0.9467 0.9500 0.9453 -
CRD SM 0.5012 1.0012 0.7920 0.4999
SSE 0.1076 0.1108 0.0900 0.0106
ESE 0.1064 0.1101 0.0892 -
IESE 0.1064 0.1092 0.0881 -
MSE 0.0229 0.0244 0.0162 -
C95% 0.9447 0.9487 0.9480 -
Doubly0 SM 0.5035 1.0010 0.7920 0.5261
SSE 0.1091 0.1120 0.0914 0.0116
ESE 0.1077 0.1105 0.0896 -
IESE 0.1078 0.1095 0.0886 -
MSE 0.0236 0.0247 0.0165 -
C95% 0.9447 0.9507 0.9407 -
Doubly3 SM 0.5040 1.0002 0.7919 0.5328
SSE 0.1090 0.1067 0.0914 0.0063
ESE 0.1076 0.1092 0.0897 -
IESE 0.1078 0.1085 0.0887 -
MSE 0.0235 0.0233 0.0165 -
C95% 0.9473 0.9527 0.9413 -
Doubly7 SM 0.5034 1.0009 0.7919 0.5335
SSE 0.1086 0.1057 0.0898 0.0052
ESE 0.1076 0.1090 0.0897 -
IESE 0.1078 0.1083 0.0888 -
MSE 0.0234 0.0231 0.0162 -
C95% 0.9460 0.9560 0.9467 -
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2.5 Application to Real Data
Through simulation, we have shown in x 2.4, that the asymptotic standard errors
of the estimated parameters based on the inuence function (IESE) and the Hessian
Matrix (ESE), were similar in value to the simulated standard errors (SSE) (see Tables
2.1 - 2.5). In this section, we apply the techniques proposed in this chapter to real
data obtained from a multi-center clinical trial. The trials were conducted at eight
dierent centers for the purpose of comparing two cream preparations (active drug,
control) for treating an infection (Beitler and Landis (1985)). GLMM can be used
conceptually in a multi-center clinical trial when a sample of centers is selected from a
large number of centers and the number of centers selected is reasonably large. Grizzle
(1987) suggested that occasionally, it is preferable to consider center eects as random
eects rather than xed eects even if the sample of centers was not randomly chosen.
He also noted that the number of centers selected has to be large enough for consistent
estimation of the model parameters in GLMM. Though the data in this application
was collected from only eight medical centers, a total of 273 patients participated
in the study. The data, taken from Agresti and Hartzel (2000) are summarized in
Table 2.6. Agresti and Hartzel (2000) had considered several models for estimating
the treatment eect. However, we will discuss only the GLM with xed center eects
and the GLMM. The model with xed center eects we considered is given by,
logit[P (Yij = 1jxijA)] = FxijA + uFj ; i = 1; 2;    ; nj and j = 1; 2;    ; J; (2.16)
where the center eects uFj , j = 1; 2;    ; J are assumed to be xed and F is the
treatment eect that is assumed to be constant over centers. We also considered a
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GLMM with logit link function dened by
logit[P (Yij = 1juj; xijA)] = 0 + AxijA + uj; i = 1; 2;    ; nj and j = 1; 2;    ; J;
(2.17)
where 0 is the overall intercept, A is the treatment eect that is assumed to be con-
stant over centers, and the random center eect uj, j = 1; 2;    ; J , are independent
normal random variables with mean zero and common center variance 2.
Table 2.6: Clinical trial relating treatment to response for eight centres.
Centre Treatment Response Total
Success Failure
1 Drug 11 25 36
Control 10 27 37
2 Drug 16 4 20
Control 22 10 32
3 Drug 14 5 19
Control 7 12 19
4 Drug 2 14 16
Control 1 16 17
5 Drug 6 11 17
Control 0 12 12
6 Drug 1 10 11
Control 0 10 10
7 Drug 1 4 5
Control 1 8 9
8 Drug 4 2 6
Control 6 1 7
Total Drug 55 75 130
Control 47 96 143
Though models (2.16) and (2.17) appear to be similar in structure the methods for es-
timating the model parameters are completely dierent. In fact, the overall intercept
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0 in (2.17) cannot be estimated separately in (2.16) because the overall intercept is
included in center eects. Indeed, our main objective is to estimate the treatment
eect eciently and not how to estimate the overall intercept and center eects sep-
arately. We will apply two separate iteration methods for estimating the parameters
of the models. The rst method is the usual approach based on the gradient vector
and the Hessian matrix dened in the section 2.2 of this chapter. We introduce a new
approach, in this section, based entirely on the inuence function given by
^new = ^old +
1
J
JX
j=1
IF (yj;; F
)j=^old ; (2.18)
where
1
J
JX
j=1
IF (yj;; F
) =  (JCS) 1
JX
j=1
B0yjA0yj with CS given by (2.15) and A0yj ,
and B0yj dened by (2.10).
We observe that in Table 2.6, the responses of all patients assigned to the control
group in Centers 5 and 6 were failures. As a result, following Agresti and Hartzel
(2000) we will examine whether centers with 0 successes have any inuence on the
results of descriptive and inferential analyses. To investigate the eect which centers
with 0 successes for treatment has on inference, we will examine the p values of the
Wald test for treatment eect. More specically, the Wald Statistic (see Lyles, Lin
and Williamson (2007)) 2c = ^
2
A=V ar(^A) and the corresponding p value for testing
H0 : A = 0 versus the alternative Ha : A > 0 will be computed under three scenar-
ios, namely, (a) DATA 1 which is the original data shown in Table 2.6; (b) DATA
2 which excludes data from centers with zero responses in the control group; and (c)
DATA 3 which combines the data from Centers 5, 6 and 7. The results from this
analysis are shown in Table 2.7.
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Table 2.7: Values of the D optimality criterion, the Wald Statistic and their cor-
reponding p values for testing the signicance of treatment eect computed using
DATA 1, DATA 2 and DATA 3, and estimated parameters and their standard er-
rors based on (a) the Hessian matrix denoted by Estimate and ESE respectively; (b)
the inuence function approach in (2.18) denoted by IEstimate and IESE respectively
for the parameters in model (2.17) and the parameters in model (2.16) denoted by
FEstimate and FESE respectively.
Data Quantity ^0 ^A=^F ^ D optimality Wald p value
Statistics
DATA 1 (a) Estimate -1.1894 0.7385 1.3971
203.5655 6.044 0.014
ESE 0.5803 0.3004 0.4196
(b) IEstimate -1.1894 0.7385 1.3971
564.1102 5.806 0.016
IESE 0.6367 0.3065 0.2419
FEstimate
-
0.7766
- - - -
FESE 0.3067
DATA 2 (a) Estimate -0.6605 0.5548 1.2720
166.1339 3.102 0.078
ESE 0.5834 0.3150 0.4372
(b) IEstimate -0.6605 0.5549 1.2720
829.5909 3.970 0.046
IESE 0.5819 0.2785 0.2238
FEstimate
-
0.5754
- - - -
FESE 0.3205
DATA 3 (a) Estimate -0.8096 0.7440 1.3297
166.2647 6.150 0.013
ESE 0.6167 0.3000 0.4338
(b) IEstimate -0.8097 0.7441 1.3297
656.4324 5.427 0.020
IESE 0.6852 0.3194 0.2102
FEstimate
-
0.7774
- - - -
FESE 0.3050
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We had mentioned earlier that our main objective is to estimate treatment eect
eciently while maximizing the number of patients assigned to the best treatment.
The results in Table 2.7 show that estimates of the treatment eects, overall intercept
and the standard deviation  obtained from the two methods are about the same in
magnitude within DATA 1, DATA 2 and DATA 3. That is, the presence of zero
response does not appear to aect the parameter estimates. However, the standard
errors of the estimates obtained from the two methods are, in most cases, dierent in
value with noticeably larger dierences in SE(^0) and SE(^). For instance, ESE(^0)
= 0.5803 and IESE(^0) = 0.6367 and ESE(^) = 0.4196 and IESE(^) = 0.2419,
whereas ESE(^A=^F ) = 0.3004 and IESE(^A=^F ) = 0.3065 for DATA 1. The
same pattern is replicated in the results for DATA 3. In these cases, we observe that
IESE(^0) > ESE(^0) while IESE(^) < ESE(^). These results are reasonable since
0 + uj = u
F
j for j = 1; 2;    ; J: Also, the estimation method for GLMM estimates
these eects separately while these eects cannot be separated in the model (2.16).
It is interesting to note that the patterns in the standard errors of ^0 and ^A=^F de-
scribed above are reversed when the data for centers with zero responses in the control
group are excluded (DATA 2) when estimating the model parameters. In this case,
IESE(^0) = 0.5819 is slightly less than ESE(^0) = 0.5834 and IESE(^A=^F ) =
0.2785 is also less than ESE(^A=^F ) = 0.3150. Given the small number of centers for
which data was available, the change in pattern may be attributed to the cumulative
reduction in the total number of responses in DATA 2 from 130 to 102 in the treat-
ment group and from 143 to 121 in the control group. More specically, the number
of successes and failures reduced from 55 to 48 and from 75 to 54 respectively in the
treatment group and from 96 to 74 failures in the control group. We note that the
patterns were the same in DATA 1 and in DATA 3 where there was no reduction
in the overall number of responses.
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Given the dierences between the standard error estimates obtained from the two
methods of estimation we examined the D-optimality criterion in order to compare
the covariance matrices of the estimates. Also, this D-optimality is computed by the
determinant of Hessian matrix. The results in Table 2.7 show that at the nal stage of
the iteration process, estimates based on the inuence function approach consistently
maximized the determinant of the information matrix. For instance the value of
the D-optimality criterion based on the Hessian matrix approach and the inuence
function approach were 203.56 and 564.11 respectively for DATA 1 and 166.13 and
829.59 respectively for DATA 2. These results indicate that when compared to the
method based on the Hessian matrix, the inuence function iteration method searches
for solutions in a neighborhood that is closer to the vector of true parameters. Thus,
the inuence function estimate will, in general, be closer to the true parameter. The
results of our simulation studies with a large number of centers shown in Tables 2.1
- 2.5 also conrms this conclusion since the values of IESE are, in general, smaller
when compared with the values of ESE for all parameter estimates. Concerning the
Wald test for signicance of treatment eect, we observe that the p-values are about
the same in magnitude for DATA 1 and DATA 3 irrespective of the method of
iteration used in estimating the parameters. However, when the estimation is based
on the Hessian matrix, the p-values change rapidly from 0.014, under the original data
(DATA 1), to 0.078 once Centers 5 and 6 with 0 successes were deleted from the data
(DATA 2). This then leads to contradictory interpretations of the eect of treatments
at 5% level of signicance. On the other hand, the eect of excluding centers with
0 successes from the data on the the p-values is not as severe and lead to the same
conclusion for DATA 1, DATA 2 and DATA 3 when the estimation is based on
the inuence function. Thus, for this data under consideration the inuence function
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approach appear to lead to a more stable result irrespective of whether centers with 0
successes are included or excluded from the data. The approach based on the Hessian
matrix is however not so stable. These results clearly highlight the need for further
research on the inuence function method of estimation in generalized linear models.
2.6 Conclusion
In this chapter, we have discussed a generalized linear mixed model for analyzing
data arising from the application of response-adaptive designs in multi-center clinical
trials. We have shown that the estimators of the model parameters are consistent and
asymptotically normally distributed. We have also introduced a new iteration method
based entirely on the inuence function of the parameter estimates. Previously, the
computation of the asymptotic variance of the regression parameter estimators have
been based entirely on the inverse of the Hessian matrix obtained from the likelihood
function. We have now provided an alternative, in this chapter, by deriving a closed
form expression for the asymptotic variance of the regression parameter estimators
based on an inuence function approach. To our knowledge, such a closed form ex-
pression does not currently exist in the literature. In fact, our asymptotic approach
does not depend on the selection criteria for treatment assignments. These selection
criteria for treatment assignments include the family of response-adaptive designs and
the completely randomized design. In our simulation studies we have demonstrated
that estimates of the asymptotic variance computed from the closed form expression
we derived compare favourably well with the true values obtained directly from simu-
lation. Thus, in practice the IESE can be used to estimate the asymptotic variance of
the regression parameter estimators. We have also demonstrated through simulation
that response-adaptive designs are more ethically and morally desirable because they
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assign the potentially better treatment to more patients and that the design vari-
ability improves with appropriate choice of the parameter in the allocation function
of Hu and Zhang (2004). Moreover, the estimated 95% coverage probabilities based
on the normal distribution were shown to be unbiased. This clearly indicates that
the maximum likelihood approach with the Gauss-Hermite quadrature approxima-
tion performs very well in estimating the parameters of the GLMM. Finally, we note
that the Gauss-Hermite quadrature for integral approximation as well as the inuence
function technique for deriving the asymptotic properties can be easily extended to
generalized linear mixed models based on the exponential family.
Chapter 3
Estimation of a Generalized Linear
Model for Adaptive Designs in
Multi-Center Clinical Trials
3.1 Introduction
In Chapter 2, we assumed the GLMM as an ideal model and investigated the eciency
and ethics of participating patients between RA designs and equal allocation. Also,
we applied separate randomization to each center. In this chapter, we assume that
center eects are xed eects. Therefore, we consider the generalized linear model
(GLM) is an ideal model. The common randomization for treatment assignments
is applied to all medical centers. We examine the asymptotic theories for a general
class of adaptive designs assuming the GLM as an ideal model. Also, we compare the
eciency and ethics among RA, CARA, and Completely Randomized (CR) design
under this assumption.
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In this chapter, we introduce the logit model which includes treatment by covariate
interactions and discuss estimation method of model parameters in x 3.2. We pro-
vide a procedure for Covariate-Adjusted Response-Adaptive designs in x 3.3. The x
3.4 deals with proposed conditions for asymptotic properties of parameter estimates
for CARA designs. We discuss a odds-ratio-based target allocation proportion for
Response-Adaptive design in x 3.5. The theoretical results in x 3.4 are validated
through simulation studies in x 3.6. Finally, conclusions are provided in x 3.7.
3.2 The Logit Model and Parameter Estimation
In this section, we describe the logit model and the estimation method for model
parameters for comparing two treatments, which are treatment A and treatment B,
when other associated categorical covariates are considered. The logit model is a
well-known model for constructing the relationship between binary responses and as-
sociated covariates. Moreover, it is easy to interpret estimates in the logit model if
there is no interaction eects in the model. However, it is not easy to interpret the
estimates if the interaction terms are signicant in the logit model [Ai and Norton
(2003)] . In this chapter, we assume that responses are binary, which is either success
or failure, so the logit model was chosen to establish a linkage between the responses
and covariates. Let n be the total number of patients who were recruited and assigned
one and only one treatment from two treatments at the end of a clinical trial. The
response and treatment assignment of patient i are dened by (1.7).
Also, let Z0i = (Zi1;    ; Zip) be the p dimensional vector of covariate information of
patient i, i = 1; 2;    ; n. Here, one of the covariates in the p-dimensional vector
Zi may represent centers to account for center eects. We dene fv1;v2;    ;vmg
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as the mutually exclusive conguration levels of Z. That is, a typical patient be-
longs to one and only from these categories. When patients enter sequentially into
the clinical trial, we assume that the experimenter knows the value of the random
variable Z before entering a patient into a medical clinic and we assume that the
joint probability mass function of Z follows multinomial distribution with unknown
parameters, but these parameters do not depend on model parameters which is de-
ned in (3.1). Let us assume that the probability value of vh; P (Z = vh) = h; h =
1; 2;    ;m, then
mX
h=1
h = 1. Also, zi is the observed value of covariate vector of pa-
tient i. Furthermore, let Xi = (X1A; X2A;    ; XiA) and Yi = (Y1; Y2;    ; Yi) be
the sigma algebras generated by treatment assignments and responses respectively.
Dene C(zi) = (z
0
1; z
0
2;    ; z0i)0 as the history of covariates and Fi = (Xi;Yi).
Consider the logit model:
logit[P (Yi = 1jxiA; zi)] = xiAA + 0 + z0i + xiAz0i; for i = 1; 2;    ; n; (3.1)
where  = (1; 2;    ; p)0 are the main eects of covariates and  = (1; 2;    ; p)0
are the treatment by covariates interaction eects. Also, A is the eect of treat-
ment A compared to treatment B, 0 is the intercept term in this model. There-
fore, the probability mass function for the random variables fYi; i = 1; 2;    ; ng, is
P (Yi = yijxiA; zi) = [1 + exp( w0i)] yi [1 + exp(w0i)] (1 yi), where wi = (xiA; 1; z0i; xiAz0i)0,
 = (A; 0;
0; 0)0 is a q := 2(p + 1) dimensional vector. Also we assume that
 belongs to an admissible set 
(0)  <q; 
(0) is open and convex in <q, where
0 = (A0; 00;
0
0; 
0
0)
0 is the q-dimensional vector of true unknown parameters, which
we can estimate by the method of ML. For the logit model in (3.1), it can be shown
that
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E(YijxiA; zi) = [1 + exp( w0i)] 1, and V ar(YijxiA; zi) = exp( w0i)[1 + exp( w0i)] 2. The like-
lihood function can be written as
Ln() =
nY
i=1
[iA(zi)]
xiA [1  iA(zi)](1 xiA)[1 + exp( w0i)] yi [1 + exp(w0i)] (1 yi); (3.2)
where iA(zi) = P [XiA = 1jFi 1; C(zi 1); zi]. Then, the log-likelihood function `n() and
the score function of the log-likelihood are given by
`n() = lnh(~) 
nX
i=1
yi ln[1 + exp( w0i)] 
nX
i=1
(1  yi) ln[1 + exp(w0i)]; (3.3)
and
sn() = `
0
n() =
nX
i=1
yiwi  
nX
i=1
[1 + exp( w0i)] 1wi; (3.4)
where h(~) =
nY
i=1
[iA(zi)]
xiA [1  iA(zi)](1 xiA) and `0n() =
@`n()
@
. We then solve the ML
estimating equation
`0n() = 0; (3.5)
to obtain the ML estimates of the model parameters.
The second derivative of the log-likelihood function called the observed Fisher infor-
mation matrix
Fn() =
nX
i=1
exp( w0i)[1 + exp( w0i)] 2wiw0i: (3.6)
is used in the Newton-Raphson iteration procedure
^new = ^old + [Fn()]
 1
=^old
[sn()]=^old ;
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to obtain the MLE ^n = (^A;n; ^0;n; ^
0
n; 
0
n)
0 of 0 = (A0; 00; 00; 
0
0)
0 which is the
vector of true model parameters. The asymptotic distribution of the MLE ^n will be
discussed in x 3.4.
3.3 The Covariate-Adjusted Response-Adaptive De-
sign (CARA)
Several authors have noted that minimum information is required to get ML estimates
[Silvapulle (1981), Albert (1984), and Santner and Duy (1986)]. If sequential trial
gets minimum information, then we are able to compute the inverse of the Hessian
matrix. Thus, we need initial information to obtain ML estimates of model parame-
ters in (3.1) as a result of the application of CARA design. Before getting minimum
information for which
@`n()
@
= 0 is estimable, equal allocation is applied for treatment
assignments. Suppose the rst n0 number of patients' information is enough to solve
the equation in (3.5) and
@`n()
@
= 0 is estimable for all n  n0.
We evaluate some quantities for patient (n + 1) having the covariate information
zn+1. If this patient is assigned to treatment A, the expected success probability
of this patient becomes Pn+1;A = [1 + exp( ^A;n   ^0;n   z0n+1^n   z0n+1^n)] 1. Similarly,
if this patient is assigned to treatment B, the expected success probability of this
patient, Pn+1;B = [1 + exp( ^0;n   z0n+1^n] 1. Then, the model based odds ratio for
comparing treatment A to treatment B is xm =
Pn+1;A
(1  Pn+1;A)
(1  Pn+1;B)
Pn+1;B
= exp(^A;n +
z0n+1^n). Rosenberger, Vidyashankar and Agarwal (2001) applied the most natural
mapping to obtain the treatment assignment function, f : [0;1)! [0; 1], dened by
f(x) =
x
x+ 1
: (3.7)
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Using this function, the allocation probability to treatment A becomes
[n+1]A(zn+1) = f1 + exp[ (^A;n + z0n+1^n)]g 1: (3.8)
As an example, suppose that patient i belongs to the vh group. We thus allocate
treatment A to patient i with the following probability:
iA(vh) = P (XiA = 1jFi 1; C(zi 1); zi = vh) = f1 + exp[ (^A;(i 1) + v0h^i 1)]g 1; (3.9)
where i > n0 and n0 is the initial number of patients to whom treatments were
assigned using equal allocation. We note that this is one example of a CARA design.
3.4 Asymptotics of Parameter Estimates for CARA
Dene the subgroup of patient indices having the vh (h = 1; 2;    ;m) covariates
conguration level as
J (h)n = fi : zi = vh; i = 1; 2;    ; ng:
Since the clinical trial in this study is sequential trial and patients arrive sequentially
to the clinic, we dene
J (h)1 = fi : zi = vh; i = 1; 2;       g;
Next, we describe the subgroup of patients belongs to stratum h. We dene a set
J (h) = f(i; h) : zi = vh; i = 1; 2;   ng;
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where (i; h) is an ordered pair indicating that patient i belongs to stratum h. For ease
of notation we assign the rst element of J (h) as 1, the second element as 2,    and
the last element of J (h) as nh. J
(h) can be written as
J (h) = f1; 2;    ; nhg:
For instance suppose, n = 8 and m = 4, z1 = v2; z2 = v1; z3 = v1; z4 = v3; z5 =
v4; z6 = v2; z7 = v4; z8 = v2. Then, the set
J (1) = f(2; 1); (3; 1)g;
identies the patient 2 and patient 3 belong to stratum 1, n1 = 2, and J
(1) = f1; 2g.
The set J (h) contains nh number of patient indices with n =
mX
h=1
nh. We have iA(vh)
is the probability of patient i assigned to treatment A if patient i belongs to vh group,
for i = 1; 2;    ; n and h = 1; 2;    ;m. In fact, we do not know the format of iA(vh).
In the next Lemma, we discuss the average of these iA(vh) converges almost surely
the average of patients assigned to treatment A when we x h, h = 1; 2;    ;m.
Lemma 3.4.1. For a group of patients having vh covariates conguration level, we
have
NAh(n)
nh
  1
nh
X
i2J(h)n
iA(vh)
a:s:  ! 0 as nh !1, where NAh(n) =
X
i2J(h)n
XiA is the number
of patients assigned to treatment A in vh group, NBh(n) = nh NAh(n), and nh is the
number of patients in vh group for h = 1; 2;    ;m. Also, iA(vh) is the probability of
patient i assigned to treatment A if patient i belongs to vh group, for i = 1; 2;    ; n
and h = 1; 2;    ;m.
Proof. For a xed h = 1; 2;    ;m; dene
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Sn(vh) =
nX
i
I[zi = vh]fXiA   iA(vh)g =
X
i2J(h)n
fXiA   iA(vh)g, where I is an indicator func-
tion. Let us consider
Sn+1(vh)  Sn(vh) = I[zn+1 = vh]fX(n+1)A   (n+1)A(zn+1)g.
Case 1: If zn+1 = vh,
E[Sn+1(vh)  Sn(vh)jFn; C(zn); zn+1] = EfX(n+1)AjFn; C(zn); zn+1 = vhg   (n+1)A(vh)
= PfX(n+1)A = 1jFn; C(zn); zn+1 = vhg   (n+1)A(vh)
= 0:
Case 2: If zn+1 6= vh, then Sn+1(vh)  Sn(vh) = 0: So that
E[Sn+1(vh)  Sn(vh)jFn; C(zn); zn+1] = 0:
Therefore, the sequence of partial sums fSn(vh)g is a martingale. We know that
0 < jXnA   nA(vh)j < 1 for n 2 J (h)1 . It follows thatX
n2J(h)1
n 2h Ef[XnA   nA(vh)]2jFn 1; C(zn 1); zn = vhg <1. Therefore, by Theorem 1 of
Csorgo (1968) fthe strong law of large numbers for martingalesg, we obtain
lim
nh!1
1
nh
Snh(vh) = 0. Hence, the Lemma holds.
The observed Fisher information matrices are random matrices. If the average ob-
served Fisher information matrices converges to a non-random matrix, then we can
discuss the consistency of ML estimators. We require a condition for the average
observed Fisher information matrices converges to a non-random matrix. Therefore,
we initially will set a condition for this purpose. We describe this condition in the
following Assumption 3.4.1.
Assumption 3.4.1. For each h = 1; 2;    ;m, (1=nh)
X
i2J(h)n
iA(vh)
a:s:  ! A(vh) as
nh !1, where 0 < A(vh) < 1, where, iA(vh) is the treatment assignment function.
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We now introduce some new notations for elements of the observed Fisher information
matrix for mathematical convenience. Let
1
n
Fn() =
1
n
nX
i=1
Hi(), where
Hi() = g(w
0
i)
266666664
xiA xiA xiAz
0
i xiAz
0
i
xiA 1 z
0
i xiAz
0
i
xiAzi zi ziz
0
i xiAziz
0
i
xiAzi xiAzi xiAziz
0
i xiAziz
0
i
377777775
and (3.10)
g(w0i) = exp( w0i)[1+ exp( w0i)] 2. Furthermore, dene the functions of : Ah() and
Bh() as
Ah() = exp( A   0   v0h   v0h)[1 + exp( A   0   v0h   v0h)] 2
Bh() = exp( 0   v0h)[1 + exp( 0   v0h)] 2:
Conditional on Fi 1, C(zi 1), and zi, XiA follows a bernoulli distribution with the
unknown parameter. The recursive expectations can be taken from step 1 to step
n to obtain the unconditional expectation of the elements of the average observed
information matrix which is dened in (3.10). If this average expectation of the
observed Fisher information matrix converges almost surely to a non-random matrix,
then this non-random matrix is called the Fisher information matrix. In this section,
the Fisher information matrix I() is dened in Lemma 3.4.2. Lemma 3.4.2 also
describes the existence of the Fisher information matrix under some conditions.
Lemma 3.4.2. If Assumption 3.4.1 and
nh
n
a:s ! h are satised, then we have
(1=n)
nX
i=1
Ei 1fHi()g a:s:  ! I() as n!1, where the conditional expectation dened by
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Ei 1[] = ExiA [jFi 1; C(zi 1); zi], I() is the Fisher information matrix that is a non-
random matrix
I() =
266666664
I11() I12() I13() I14()
I 012() I22() I23() I24()
I013() I
0
23() I33() I34()
I014() I
0
24() I
0
34() I44()
377777775
; (3.11)
where  2 
(0). Moreover, Hi() is dened in (3.10) for i = 1; 2;    ; n and nh is
the number of patients in vh group.
Proof. First we note that I12() = I11(), I14() = I24() = I13(), and I44() =
I34(). Therefore, we have the following results for the components of I().
1
n
nX
i=1
Ei 1fg(w0i)xiAg =
1
n
nX
i=1
Efg(w0i)xiAjFi 1; C(zi 1); zig
=
1
n
nX
i=1
mX
h=1
I[zi = vh]Ah()iA(zi)
=
mX
h=1
nX
i=1
1
n
I[zi = vh]Ah()iA(zi)
=
mX
h=1
nh
n
Ah()
24 1
nh
X
i2J(h)n
iA(vh)
35
a:s:  !
mX
h=1
hAh()A(vh) = I11() [because of
nh
n
a:s  ! h; and
the Assumption 3:4:1:]
1
n
nX
i=1
Ei 1fg(w0i)g =
1
n
nX
i=1
Efg(w0i)jFi 1; C(zi 1); zig
=
1
n
nX
i=1
mX
h=1
I[zi = vh]fAh()iA(zi) + Bh()[1  iA(zi)]g
=
mX
h=1
nh
n
8<:Ah()
24 1
nh
X
i2J(h)n
iA(vh)
35+ Bh()
241  1
nh
X
i2J(h)n
iA(vh)
359=;
a:s:  !
mX
h=1
hfAh()A(vh) + Bh()[1  A(vh)]g = I22():
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1
n
nX
i=1
Ei 1fg(w0i)xiAz0ig =
1
n
nX
i=1
Efg(w0i)xiAz0ijFi 1; C(zi 1); zig
=
1
n
nX
i=1
mX
h=1
I[zi = vh]Ah()z
0
iiA(zi)
=
mX
h=1
Ah()
1
n
nX
i=1
I[zi = vh]z
0
iiA(zi)
=
mX
h=1
Ah()
nh
n
24 1
nh
X
i2J(h)n
iA(vh)
35v0h
a:s:  !
mX
h=1
Ah()hA(vh)v
0
h = I13():
1
n
nX
i=1
Ei 1fg(w0i)z0ig =
1
n
nX
i=1
Efg(w0i)z0ijFi 1; C(zi 1); zig
=
1
n
nX
i=1
mX
h=1
I[zi = vh]fAh()iA(zi) + Bh()[1  iA(zi)]gv0h
=
mX
h=1
nh
n
8<:Ah()
24 1
nh
X
i2J(h)n
iA(vh)
35+ Bh()
241  1
nh
X
i2J(h)n
iA(vh)
359=;v0h
a:s:  !
mX
h=1
hfAh()A(vh) + Bh()[1  A(vh)]gv0h = I23():
1
n
nX
i=1
Ei 1fg(w0i)ziz0ig =
1
n
nX
i=1
Efg(w0i)ziz0ijFi 1; C(zi 1); zig
=
1
n
nX
i=1
mX
h=1
I[zi = vh]fAh()iA(zi) + Bh()[1  iA(zi)])gvhv0h
=
mX
h=1
nh
n
8<:Ah()
24 1
nh
X
i2J(h)n
iA(vh)
35+ Bh()
241  1
nh
X
i2J(h)n
iA(vh)
359=;vhv0h
a:s:  !
mX
h=1
hfAh()A(vh) + Bh()[1  A(vh)]gvhv0h = I33():
1
n
nX
i=1
Ei 1fg(w0i)xiAziz0ig =
1
n
nX
i=1
Efg(w0i)xiAziz0ijFi 1; C(zi 1); zig
=
1
n
nX
i=1
mX
h=1
I[zi = vh]Ah()iA(zi)vhv
0
h
=
mX
h=1
nh
n
Ah()
24 1
nh
X
i2J(h)n
iA(vh)
35vhv0h
a:s:  !
mX
h=1
hAh()A(vh)vhv
0
h = I34():
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Therefore, (1=n)
nX
i=1
Ei 1fHi()g a:s:  ! I() as n!1.
The next Lemma states that the average observed Fisher information matrix converges
almost surely to the Fisher information matrix I() under some conditions.
Lemma 3.4.3. If the Assumption 3.4.1 and
nh
n
a:s ! h are satised, then the average
observed Fisher information matrix, (1=n)Fn(), converges almost surely to I(),
where  2 
(0), nh is the number of patients in vh group, and I() is a Fisher
information matrix.
Proof. Dene NAh(n) =
X
i2J(h)n
xiA as the number of patients assigned to treatment A
in vh group and NBh(n) = nh  NAh(n). Then, the following results hold.
1
n
nX
i=1
g(w0i)xiA =
1
n
mX
h=1
Ah()NAh(n)
=
mX
h=1
Ah()
nh
n
NAh(n)
nh
a.s.
mX
h=1
Ah()
nh
n
24 1
nh
X
i2J(h)n
iA(vh)
35
a:s:  !
mX
h=1
Ah()hA(vh) = I11()
1
n
nX
i=1
g(w0i)xiAz
0
i =
1
n
mX
h=1
Ah()NAh(n)v
0
h
=
mX
h=1
Ah()
nh
n
NAh(n)
nh
v0h
a.s.
mX
h=1
Ah()
nh
n
24 1
nh
X
i2J(h)n
iA(vh)
35v0h
a:s:  !
mX
h=1
Ah()hA(vh)v
0
h = I13()
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1
n
nX
i=1
g(w0i) =
1
n
mX
h=1
fAh()NAh(h) + Bh() [nh  NAh(h)]g
=
mX
h=1
nh
n

Ah()
NAh(h)
nh
+ Bh()

1  NAh(h)
nh

a.s.
mX
h=1
nh
n
8<:Ah()
24 1
nh
X
i2J(h)n
iA(vh)
35+ Bh()
241  1
nh
X
i2J(h)n
iA(vh)
359=;
a:s:  !
mX
h=1
hfAh()A(vh) + Bh()[1  A(vh)]g = I22()
1
n
nX
i=1
g(w0i)z
0
i =
1
n
mX
h=1
fAh()NAh(n) + Bh() [nh  NAh(n)]gv0h
=
mX
h=1
nh
n

Ah()
NAh(n)
nh
+ Bh()

1  NAh(n)
nh

v0h
a.s.
mX
h=1
nh
n
8<:Ah()
24 1
nh
X
i2J(h)n
iA(vh)
35+ Bh()
241  1
nh
X
i2J(h)n
iA(vh)
359=;v0h
a:s:  !
mX
h=1
hfAh()A(vh) + Bh()[1  A(vh)]gv0h = I23()
1
n
nX
i=1
g(w0i)ziz
0
i =
1
n
mX
h=1
fAh()NAh(n) + Bh() [nh  NAh(n)]gvhv0h
=
mX
h=1
nh
n

Ah()
NAh(n)
nh
+ Bh()

1  NAh(n)
nh

vhv
0
h
a.s.
mX
h=1
nh
n
8<:Ah()
24 1
nh
X
i2J(h)n
iA(vh)
35+ Bh()
241  1
nh
X
i2J(h)n
iA(vh)
359=;vhv0h
a:s:  !
mX
h=1
hfAh()A(vh) + Bh()[1  A(vh)]gvhv0h = I33()
1
n
nX
i=1
g(w0i)xiAziz
0
i =
1
n
mX
h=1
Ah()NAh(n)vhv
0
h
=
mX
h=1
nh
n
Ah()
NAh(n)
nh
vhv
0
h
a.s.
mX
h=1
nh
n
Ah()
24 1
nh
X
i2J(h)n
iA(vh)
35vhv0h
a:s:  !
mX
h=1
Ah()A(vh)hvhv
0
h = I34()
71
In Lemma 3.4.3 we show that the average observed Fisher information, (1=n)Fn(),
converges almost surely and pointwise to I() for each  2 
(0). The next Lemma
3.4.4 states that (1=n)Fn() converges almost surely and uniformly on a neighbour-
hood of 0 under the same conditions in Lemma 3.4.3.
Lemma 3.4.4. If the Assumption 3.4.1, and
nh
n
a:s:  ! h are satised with m < 1
and q <1, then we can nd that there exists an open ball G  
(0), 0 2 G such
that the average observed Fisher information (1=n)Fn() uniformly and almost surely
converges to I() on G, where nh is the number of patients in vh group.
Proof. From Lemma 3.4.3 we have that (1=n)Fn() almost surely converges on 
(0).
First we consider the element (1; 1) := (1=n)
Pn
i=1 g(w
0
i)xiA =
Pm
h=1 Ah()fNAh(n)=ng
of the matrix (1=n)Fn(). Let  > 0, for h = 1; 2;    ;m.
From Lemma 3.4.3 we have fNAh(n)=ng a:s:  ! hA(vh) as n ! 1 under Assump-
tion (3.4.1) and
nh
n
a:s ! h. The function Ah() : 
(0)! < is a bounded function.
Therefore, there existsN11h 2 N such that jfNAh(n)=ng   hA(vh)j < =1:5
mX
h=1
Ah(0)
for all n  N11h a.s. Furthermore, Ah() is a continuous function, so lim
!0
Ah() = Ah(0).
Therefore, there exists 11h > 0 such that Ah() < 1:5Ah(0) for all  2 G11h , where
G11h = f :k    0 k< 11hg. We then obtain
Ah()
NAh(n)n   hA(vh)
 < [Ah(0)]= mX
h=1
Ah(0): (3.12)
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Consider

mX
h=1
Ah()
NAh(n)
n
 
mX
h=1
Ah()hA(vh)
 =

mX
h=1
Ah()

NAh(n)
n
  hA(vh)


mX
h=1
Ah()
NAh(n)n   hA(vh)

< : (3.13)
Therefore,

mX
h=1
Ah()
NAh(n)
n
 
mX
h=1
Ah()phA(vh)
 <  for all n  N11 and for all
 2 G11, where N11 = max
1hm
N11h, 11 = min
1hm
11h, and G11 = f :k    0 k< 11g.
It follows that
1
n
nX
i=1
g(w0i)xiA uniformly and almost surely converges on G11. Sim-
ilarly, we can show that there exists Nij = max
1hm
Nijh and ij = min
1hm
ijh such that
the (i; j)th element of the matrix (1=n)Fn() uniformly and almost surely converges
on Gij, where Gij = f :k  0 k< ijg. Since q is nite, there exists N = max
1i;jq
Nij
and  = min
1i;jq
ij such that (1=n)Fn() uniformly and almost surely converges to I()
on G, where G = f :k    0 k< g.
Lemma 3.4.5. If the Assumption 3.4.1 is satised with m < 1 and q < 1, then
(1=n)in uniformly and almost surely converges to i() as n!1 for i = 1; 2;    ; q,
where 1n  2n     qn and 1()  2()     q() are eigenvalues of the sym-
metric matrices Fn() and I() respectively, Fn() is an observed Fisher information
matrix, and I() is a Fisher information matrix.
Proof. According to Lemma 2.1.19 (Homan-Wielandt) in Anderson, Alice and
Ofer (2010), we have
qX
i=1
j(1=n)in   i()j2  tracef(1=n)Fn()  I()g2: (3.14)
Let the (j; k)th element of the matrices (1=n)Fn() and I() be dened by (1=n)Fjkn()
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and Ijk(), respectively, where j; k = 1; 2;    ; q. Let  > 0. From Lemma 3.4.4, there
exists N 2 N and  > 0 such that (1=n)Fn() uniformly and almost surely converges
to I() on G, where G = f :k    0 k< g. Therefore, there exists N 2 N and
 > 0 such that (1=n)Fjkn() uniformly and almost surely converges to Ijk() on G,
where G = f :k    0 k< g for all 1  j; k  q.
Then, there exists N 2 N and  > 0 such that j(1=n)Fjkn()  Ijk()j2 < 2=q2 on G
for all  2 G = f :k    0 k< g, all n  N , where 1  j; k  q. Furthermore,
tracef(1=n)Fn()  I()g2 =
qX
j=1
qX
k=1
j(1=n)Fjkn()  Ijk()j2 < 2 (3.15)
Because (1=n)Fn()  I() is a symmetric matrix. From (3.14) and (3.15) we obtain
qX
i=1
j(1=n)in   i()j2 < 2. Therefore, there exists N 2 N and  > 0 such that
j(1=n)in   i()j <  for all n  N , all  2 G = f :k    0 k< g with 1  i  q.
Hence the Lemma holds.
Assumption 3.4.2. I(0) is a positive denite matrix, where 0 is the q dimensional
true vector of parameters, and I(0) is a Fisher information matrix.
Lemma 3.4.6. If the Assumptions 3.4.1 and 3.4.2 are satised with m < 1, and
q <1, then the following results hold
(i) There exists an open ball G  
(0) and N 2 N such that the Fisher infor-
mation matrix I() is a positive denite matrix for all  2 G and the observed
Fisher information matrix Fn() is positive denite for all n  N and for all
 2 G.
(ii) ^n
a:s ! 0 as n!1, where ^n is the MLE of 0.
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Proof. (i) From Lemma (3.4.5), we have that (1=n)minFn() uniformly and almost
surely converges to 1() as n!1, where minFn() is the minimum eigenvalue
of Fn(). Therefore, there exists an open ball G1 = f :k  0 k< 1g  
(0)
and N 2 N such that 1()  0:51(0) < (1=n)minFn() for all  2 G1 and
for all n  N .
By applying Lemma 3.4.4, (1=n)Fn() uniformly and almost surely converges
to I() on G2. Moreover, (1=n)Fn() is continuous on G2. From the uniform
convergence theorem, we have that I() is continuous on G2. Therefore, the
coecients of the polynomial for computing the eigenvalues of I() are continu-
ous and nite on G2, since m is nite. The eigenvalues of I() are roots of this
polynomial. Therefore, the eigenvalues of I() are continuous functions on G2
fOrtega (1932), page 45g.
It follows that, 1() is a continuous function of  on G2. So we have lim
!0
1() = 1(0).
Then there exists 2 > 0 such that 0:61(0) < 1() for all  2 G2 = f :k
   0 k< 2g. Let  = minf1; 2g. Then there exists an open ball G = f :k
   0 k< g  
(0) and N 2 N such that 0 < 0:11(0) < 1
n
minFn() and
0 < 0:61(0) < 1() for all  2 G and for all n  N . Hence part (i) of this
Lemma holds.
(ii) From part (i), we have 0:11(0) <
1
n
minFn(0) for all n  N . Therefore,
minFn(0)
a:s !1: (3.16)
Furthermore,
1
n
maxFn(0)
a:s ! q(0), where q(0) is the maximum eigenvalue
of the positive denite matrix I(0). Let  > 0 then, there exits N3 2 N such that
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q(0)    < 1
n
maxFn(0) < q(0) +  for all n  N3. Choose  = 0:5q(0),
then 0 < 0:5q(0) <
1
n
maxFn(0) < 1:5q(0) for all n  N3, and

1
n
maxFn(0)
1=4
< f1:5q(0)g1=4 for all n  N3 (3.17)
Let N4 = maxfN;N3g. Choose  = 2 and consider
minFn()
[maxFn(0)]1=(2+)
=
(1=n)minFn()
[(1=n)maxFn(0)]0:25
n0:75
>
0:11(0)
f1:5q(0)g0:25
= c (say) for all n > N4 and  2 G: (3.18)
Using (3.16) and (3.18) we obtain ^n
a:s ! 0 as n!1 [Theorem 2 of Fahrmeir
and Kaufmann (1985)].
Theorem 3.4.1. If the Assumptions 3.4.1 and 3.4.2 are satised with m <1, q <1,
then we have that
p
n(^n   0) is asymptotically multivariate normal in distribution
with mean 0 and variance-covariance matrix I(0)
 1, where I(0) is a Fisher infor-
mation matrix.
Proof. We have sn(0) =
nX
i=1
yiwi  
nX
i=1
[1 + exp( w0i0)] 1wi. Then
sn+1(0)  sn(0) = yn+1wn+1   [1 + exp( w0n+10)] 1wn+1.
Consider
E[sn+1(0)  sn(0)jFn; C(zn); x(n+1)A]
= E[yn+1jx(n+1)A]wn+1   [1 + exp( w0n+10)] 1wn+1
= 0.
76
Therefore E[sn+1(0)  sn(0)jFn; C(zn)] = 0.
Then fsn(0)g is a sequence of martingale arrays. Under some regularity conditions,
applying the martingale central limit theorem,
1p
n
sn(0) follows multivariate normal
distribution.
Let xn be the history of treatment assignments of all n patients. That is, xn =
(x1A; x2A;    ; xnA). Then we have
E[sn(0)jxn]
=
nX
i=1
E[yijxiA]wi  
nX
i=1
[1 + exp( w0i0)] 1wi
= 0.
Therefore,
E[sn(0)] = 0q1: (3.19)
Now,
Var[sn(0)jxn] = Var
"
nX
i=1
yiwijxn
#
=
nX
i=1
Var[yiwijxiA]
=
nX
i=1
exp( w0i0)[1 + exp( w0i0)] 2wiw0i
= Fn(0);
and, by Lemma (3.4.3)
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1
n
Var[sn(0)] =
1
n
ExnfVar[sn(0)]g+
1
n
VarxnfE[sn(0)]g
=
1
n
ExnfVar[sn(0)]g
=
1
n
ExnfFn(0)g
L ! I(0): (3.20)
Using (3.19), (3.20), and the fact that
1p
n
sn(0) follows multivariate normal distri-
bution we have that
1p
n
sn(0)  Nq[0; I(0)]: (3.21)
Apply the multivariate version of the Taylor's expansion fKonigsberger (2004), page
66g for the score function sn() to obtain
0 = sn(^n) = sn(0)  Fn(0)(^n   0) + o(k ^n   0 kq); (3.22)
where o(k ^n 0 kq) = [o1(k ^n 0 kq); o2(k ^n 0 kq);    ; oq(k ^n 0 kq)]0 and
the error vector, o(k ^n   0 kq), in (3.22) goes to 0q1 faster than k ^n   0 kq goes
to zero when ^n is near to 0.
Moreover ^n is a consistent estimator of 0 satisfying the conditions in Lemma (3.4.6).
Thus, the linear approximation in (3.22) is good enough for sn(^n). Under these
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conditions, we have that
Fn(0)(^n   0)  sn(0)
p
n(^n   0) 

1
n
Fn(0)
 1 
1p
n
sn(0)

(3.23)
since the remainder term goes faster to zero when ^n closes to 0. Using Lemma
3.4.3, we have that
1
n
Fn(0)
a:s:  ! I(0)
)

1
n
Fn(0)
 1
a:s:  ! I(0) 1 (3.24)
Therefore it follow, from (3.24), (3.21), and (3.23), we have that
p
n(^n   0)  N

0; I(0)
 1 : (3.25)
3.5 A Limiting Allocation for Response-Adaptive
Design based on the Most Natural Mapping
In x 3.3, we discussed CARA design. The model based odds-ratio that was obtained
from ML estimates and the most natural mapping were used to formulate this CARA
design. However, RA designs have been well developed in literature. Thus, this RA
designs have to be compared with CARA design. Moreover, we have many types of RA
designs in literature. But, we selected the odds-ratio-based response-adaptive design
because this design has similar formulation comparable with CARA design. In this
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section, we discuss odds-ratio-based response-adaptive designs that was introduced
by Basak et al. (2009). The odds ratio for comparing treatment A against treatment
B is given by,
OR(PAS; PBS) =
PAS
(1  PAS)
(1  PBS)
PBS
; (3.26)
where PAS and PBS are the success probabilities for those patients assigned to treat-
ment A and B, respectively.
The odds-ratio-based limiting allocation to treatment A using the most natural map-
ping is provided
(PAS; PBS) =
OR(PAS; PBS)
1 +OR(PAS; PBS)
: (3.27)
In our simulation study for this chapter, we use the allocation function of DBCD that
is dened in (1.5) to target this limiting allocation.
3.6 Simulation Studies
In this section, we validate the theoretical results we obtained in x 3.4. Suppose,
treatments A and B are to be compared among patients who have a disease, consid-
ering the covariates: gender, chronic conditions, age. The description of responses,
treatment assignments, and covariates are given by
Yi =
8>>>><>>>>:
1 if treatment is
a success,
0 otherwise.
and XiA =
8>>>><>>>>:
1 if the patient i is assigned
to treatment A,
0 otherwise.
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Zi1 =
8><>: 1 Male (55%),0 Female. and Zi2 =
8><>: 1 at least one chronic condition (60%),0 otherwise.
Zi3 =
8><>: 1 20  Age  50 (30%),0 otherwise. and Zi4 =
8><>: 1 50 < Age  65 (30%),0 otherwise.
In this simulation study, the patient responses are assumed to be instantaneous. The
following model is assumed to be the true statistical model for simulation studies,
logit[P (Yi = 1jxiA)] = xiAA + 0 + 1zi1 + 2zi2 + 3zi3 + 4zi4 + 1xiAzi1 +
2xiAzi2 + 3xiAzi3 + 4xiAzi4;
= w0i for i = 1; 2;    ; n (3.28)
where  = (A; 0;
0; 0)0 and wi = (xiA; 1; z0i; xiAz
0
i)
0. Also, P (Yi = 1jxiA) =
[1 + exp( w0i)] 1 and P (Yi = 0jxiA) = [1 + exp(w0i)] 1.
Since we have four binary covariates, Z1; Z2; Z3; Z4, we can form 16 conguration'
levels that are dened in Table 3.1.
In this simulation study, the three sets of true parameter values for the logit model
in (3.28) we selected are:
(a) A0 = 1:25; 00 = 0:50; 10 =  0:18; 20 =  0:30; 30 = 0:25; 40 = 0:10; 10 =
0:00; 20 = 0:00; 30 = 0:00; 40 = 0:00
(b) A0 = 1:25; 00 = 0:5; 10 =  0:22; 20 =  0:4; 30 = 0:2; 40 = 0:1; 10 =
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Table 3.1: The levels of congurations(CL) or strata
Level(h) z1 z2 z3 z4
S1 0 0 0 0
S2 0 0 0 1
S3 0 0 1 0
S4 0 0 1 1
S5 0 1 0 0
S6 0 1 0 1
S7 0 1 1 0
S8 0 1 1 1
S9 1 0 0 0
S10 1 0 0 1
S11 1 0 1 0
S12 1 0 1 1
S13 1 1 0 0
S14 1 1 0 1
S15 1 1 1 0
S16 1 1 1 1
0:09; 20 =  0:8; 30 = 0:06; 40 = 0:04
(c) A0 = 0; 00 = 0:25; 10 =  0:20; 20 =  0:35; 30 = 0:25; 40 = 0:15; 10 =
0:10; 20 =  1:50; 30 = 0:05; 40 = 0:05.
The set (a) represents no treatment by covariates interactions in the true model.
Thus, treatment A is the best treatment because A0 is positive. However, in sets (b)
and (c), the true model contains treatment by covaraite interactions. Thus, neither
treatment A nor treatment B is the globally best treatment. We consider these three
scenarios to conduct simulation study. The selected number of patients were 500 and
1000 to implement this simulation study through 3000 simulations.
In CARA design, the probabilities of treatment assignments depend on the current
patients' covariates. On the contrary, these probabilities does not depend on the cur-
rent patients' covariates in RA designs. In this simulation study, CARA design is
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Table 3.2: CARA, RA, and CR procedures from 3000 simulations with 500 number of
patients. The proportion of patients assigned to treatment A in stratum h (P^Ah) for
h = 1; 2;    ;m, simulated means (SM), simulated standard errors (SSE) with the model
parameters A0 = 1:25, 00 = 0:50, 10 =  0:18, 20 =  0:30, 30 = 0:25, 40 = 0:10,
10 = 0:00, 20 = 0:00, 30 = 0:00, 40 = 0:00.
Stratum h
Design Quantity S1 S2 S3 S4 S5 S6 S7 S8
CARA SM(P^Ah) 0.7308 0.7286 0.7260 0.7228 0.7305 0.7291 0.7220 0.7206
SSE(P^Ah) 0.1194 0.1422 0.1572 0.1902 0.1031 0.1255 0.1366 0.1685
RA SM(P^Ah) 0.7748 0.7734 0.7754 0.7753 0.7758 0.7768 0.7762 0.7719
SSE(P^Ah) 0.0791 0.1024 0.1122 0.1496 0.0664 0.0836 0.0939 0.1211
CR SM(P^Ah) 0.4964 0.5000 0.4995 0.4961 0.4981 0.4995 0.4994 0.5012
SSE(P^Ah) 0.0790 0.1094 0.1246 0.1712 0.0650 0.0889 0.0967 0.1360
Design Quantity S9 S10 S11 S12 S13 S14 S15 S16
CARA SM(P^Ah) 0.7316 0.7271 0.7238 0.7211 0.7309 0.7267 0.7246 0.7225
SSE(P^Ah) 0.1095 0.1367 0.1426 0.1807 0.0955 0.1202 0.1257 0.1580
RA SM(P^Ah) 0.7754 0.7736 0.7746 0.7740 0.7756 0.7754 0.7764 0.7760
SSE(P^Ah) 0.0718 0.0902 0.1014 0.1349 0.0633 0.0775 0.0838 0.1082
CR SM(P^Ah) 0.5012 0.4978 0.5011 0.4976 0.5006 0.5018 0.4990 0.5022
SSE(P^Ah) 0.0720 0.0968 0.1097 0.1538 0.0580 0.0781 0.0866 0.1247
Table 3.3: CARA, RA, and CR procedures from 3000 simulations with 500 number of
patients. The proportion of patients assigned to treatment A (P^A), the success rates of
patients (P^S), simulated means (SM), and simulated standard errors (SSE) with the model
parameters A0 = 1:25, 00 = 0:50, 10 =  0:18, 20 =  0:30, 30 = 0:25, 40 = 0:10,
10 = 0:00, 20 = 0:00, 30 = 0:00, 40 = 0:00.
Quantity CARA RA CR
SM(P^A) 0.7279 0.7752 0.4996
SSE(P^A) 0.0504 0.0455 0.0222
SM(P^S) 0.7602 0.7718 0.7044
SSE(P^S) 0.0213 0.0214 0.0202
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compared to CR design and RA design that is described in x 3.5. We have already
mentioned that neither treatment A nor treatment B is the globally best treatment if
treatment by covariate interactions exist. Thus, we compute the combined proportion
of success rates of treatment A and B, say P^S, to compare three designs because we
would not come to any conclusion based on the results that the proportion of patients
assigned to treatment A, say P^A. Furthermore, we calculated the proportion of pa-
tients assigned to treatment A for stratum h, say P^Ah, h = 1; 2;    ; 16. In fact, P^S
is a measure that can be used to compare participating patients' ethics among three
designs.
Table 3.4: CARA, RA, and CR procedures from 3000 simulations with 500 number of
patients. Simulated means (SM), simulated standard error (SSE), estimated standard error
(ESE), and coverage probability (CP) with the model parameters A0 = 1:25, 00 = 0:50,
10 =  0:18, 20 =  0:30, 30 = 0:25, 40 = 0:10, 10 = 0:00, 20 = 0:00, 30 = 0:00,
40 = 0:00.
Design Quan-
tity ^A ^0 ^1 ^2 ^3 ^4 ^1 ^2 ^3 ^4
CARA SM 1.359 0.418 -0.183 -0.294 0.226 0.082 -0.006 -0.026 0.029 0.023
SSE 0.561 0.449 0.397 0.416 0.443 0.446 0.496 0.521 0.556 0.548
ESE 0.522 0.410 0.375 0.384 0.412 0.394 0.474 0.487 0.526 0.498
CP 0.940 0.942 0.944 0.939 0.947 0.939 0.946 0.936 0.946 0.937
RA SM 1.300 0.484 -0.181 -0.315 0.274 0.105 -0.004 -0.002 -0.014 0.004
SSE 0.567 0.472 0.429 0.440 0.479 0.458 0.506 0.527 0.576 0.551
ESE 0.545 0.446 0.412 0.420 0.454 0.431 0.498 0.510 0.552 0.521
CP 0.940 0.947 0.948 0.946 0.941 0.944 0.950 0.948 0.939 0.944
CR SM 1.287 0.512 -0.190 -0.296 0.256 0.106 0.005 -0.024 0.017 0.017
SSE 0.495 0.292 0.267 0.276 0.296 0.283 0.445 0.458 0.511 0.470
ESE 0.487 0.287 0.265 0.270 0.290 0.277 0.440 0.453 0.491 0.461
CP 0.952 0.949 0.950 0.950 0.947 0.952 0.950 0.954 0.949 0.953
We also computed the simulated means (SM) to conrm the consistency of parameter
estimates. The estimated standard error (ESE) is computed using the inverse of the
Hessian matrix obtained at the nal stage of the maximization process. Also, the
simulated standard error (SSE) is calculated to validate whether ESE can be used in
real data analysis. That is, if the values of SSE and ESE are close, we can use ESE
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for real data analysis. The normal distribution based coverage probability (CP) is
computed to verify whether the parameter estimates asymptotically follow the nor-
mal distribution.
Table 3.5: CARA, RA, and CR procedures from 3000 simulations with 500 number of
patients. The proportion of patients assigned to treatment A in stratum h (P^Ah) for
h = 1; 2;    ;m, simulated means (SM), simulated standard errors (SSE) with the model
parameters A0 = 1:25, 00 = 0:5, 10 =  0:22, 20 =  0:4, 30 = 0:2, 40 = 0:1, 10 = 0:09,
20 =  0:8, 30 = 0:06, 40 = 0:04.
Stratum h
Design Quantity S1 S2 S3 S4 S5 S6 S7 S8
CARA SM(P^Ah) 0.7373 0.7402 0.7412 0.7414 0.5953 0.6035 0.6047 0.6123
SSE(P^Ah) 0.1171 0.1421 0.1522 0.1872 0.1236 0.1514 0.1618 0.1920
RA SM(P^Ah) 0.6836 0.6829 0.6844 0.6807 0.6822 0.6856 0.6848 0.6814
SSE(P^Ah) 0.0857 0.1108 0.1240 0.1661 0.0729 0.0921 0.1020 0.1341
CR SM(P^Ah) 0.4964 0.4999 0.4994 0.4961 0.4982 0.4995 0.4995 0.5012
SSE(P^Ah) 0.0790 0.1094 0.1247 0.1712 0.0651 0.0889 0.0967 0.1360
Design Quantity S9 S10 S11 S12 S13 S14 S15 S16
CARA SM(P^Ah) 0.7530 0.7554 0.7532 0.7564 0.6157 0.6232 0.6240 0.6351
SSE(P^Ah) 0.1045 0.1272 0.1347 0.1717 0.1147 0.1404 0.1477 0.1767
RA SM(P^Ah) 0.6834 0.6813 0.6835 0.6788 0.6835 0.6833 0.6841 0.6812
SSE(P^Ah) 0.0807 0.1013 0.1129 0.1507 0.0668 0.0847 0.0928 0.1229
CR SM(P^Ah) 0.5012 0.4978 0.5011 0.4978 0.5007 0.5018 0.4990 0.5022
SSE(P^Ah) 0.0720 0.0968 0.1096 0.1540 0.0580 0.0781 0.0866 0.1247
The results in Tables 3.2, 3.5, 3.8, and 3.11 show that the proportion of patients
assigned to treatment A are (i) approximately equal in each stratum for RA design,
(ii) approximately 0.5 in each stratum for CR design, and (iii) dierent in values
among strata for CARA design except in Table 3.2. This shows that the proportion
of patients assigned to treatment A are equal in each stratum for CARA design when
there is no treatment by covariate interaction in the true model [see Table 3.2].
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Table 3.6: CARA, RA, and CR procedures from 3000 simulations with 500 number of
patients. The proportion of patients assigned to treatment A (P^A), the success rates of
patients (P^S), simulated means (SM), and simulated standard errors (SSE) with the model
parameters A0 = 1:25, 00 = 0:5, 10 =  0:22, 20 =  0:4, 30 = 0:2, 40 = 0:1, 10 = 0:09,
20 =  0:8, 30 = 0:06, 40 = 0:04.
Quantity CARA RA CR
SM(P^A) 0.6664 0.6832 0.4996
SSE(P^A) 0.0535 0.0484 0.0222
SM(P^S) 0.6767 0.6750 0.6435
SSE(P^S) 0.0221 0.0217 0.0214
Table 3.7: CARA, RA, and CR procedures from 3000 simulations with 500 number of
patients. Simulated means (SM), simulated standard error (SSE), estimated standard
error (ESE), and coverage probability (CP) with the model parameters A0 = 1:25,
00 = 0:5, 10 =  0:22, 20 =  0:4, 30 = 0:2, 40 = 0:1, 10 = 0:09, 20 =  0:8,
30 = 0:06, 40 = 0:04.
Design Quan-
tity ^A ^0 ^1 ^2 ^3 ^4 ^1 ^2 ^3 ^4
CARA SM 1.353 0.415 -0.224 -0.370 0.173 0.082 0.101 -0.873 0.092 0.060
SSE 0.540 0.427 0.359 0.390 0.414 0.378 0.462 0.498 0.526 0.488
ESE 0.502 0.394 0.331 0.366 0.368 0.350 0.426 0.468 0.474 0.449
CP 0.941 0.949 0.947 0.945 0.934 0.947 0.939 0.943 0.940 0.937
RA SM 1.291 0.485 -0.227 -0.412 0.218 0.112 0.102 -0.823 0.058 0.036
SSE 0.492 0.372 0.342 0.347 0.387 0.356 0.428 0.463 0.493 0.445
ESE 0.483 0.366 0.337 0.344 0.369 0.352 0.425 0.453 0.468 0.445
CP 0.951 0.954 0.948 0.954 0.942 0.952 0.953 0.948 0.937 0.955
CR SM 1.274 0.515 -0.239 -0.408 0.212 0.102 0.114 -0.831 0.063 0.054
SSE 0.478 0.290 0.262 0.274 0.288 0.281 0.402 0.448 0.458 0.424
ESE 0.469 0.286 0.263 0.269 0.288 0.275 0.402 0.438 0.444 0.421
CP 0.954 0.948 0.952 0.947 0.950 0.946 0.950 0.948 0.950 0.949
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Table 3.8: CARA, RA, and CR procedures from 3000 simulations with 500 number
of patients. The proportion of patients assigned to treatment A in stratum h (P^Ah)
for h = 1; 2;    ;m, simulated means (SM), simulated standard errors (SSE) with
the model parameters A0 = 0, 00 = 0:25, 10 =  0:20, 20 =  0:35, 30 = 0:25,
40 = 0:15, 10 = 0:10, 20 =  1:50, 30 = 0:05, 40 = 0:05.
Stratum h
Design Quantity S1 S2 S3 S4 S5 S6 S7 S8
CARA SM(P^Ah) 0.4962 0.5072 0.5079 0.5127 0.2108 0.2239 0.2233 0.2348
SSE(P^Ah) 0.1513 0.1767 0.1913 0.2318 0.0948 0.1142 0.1254 0.1557
RA SM(P^Ah) 0.3339 0.3326 0.3345 0.3314 0.3326 0.3336 0.3342 0.3311
SSE(P^Ah) 0.0879 0.1152 0.1256 0.1704 0.0712 0.0924 0.1001 0.1356
CR SM(P^Ah) 0.4964 0.4999 0.4994 0.4961 0.4982 0.4995 0.4995 0.5012
SSE(P^Ah) 0.0790 0.1094 0.1247 0.1712 0.0651 0.0889 0.0967 0.1360
Design Quantity S9 S10 S11 S12 S13 S14 S15 S16
CARA SM(P^Ah) 0.5214 0.5275 0.5271 0.5319 0.2244 0.2368 0.2370 0.2469
SSE(P^Ah) 0.1416 0.1716 0.1778 0.2153 0.0955 0.1160 0.1209 0.1527
RA SM(P^Ah) 0.3342 0.3356 0.3315 0.3317 0.3325 0.3338 0.3339 0.3308
SSE(P^Ah) 0.0810 0.1052 0.1165 0.1522 0.0646 0.0844 0.0898 0.1253
CR SM(P^Ah) 0.5012 0.4978 0.5011 0.4978 0.5007 0.5018 0.4990 0.5022
SSE(P^Ah) 0.0720 0.0968 0.1096 0.1540 0.0580 0.0781 0.0866 0.1247
Table 3.9: CARA, RA, and CR procedures from 3000 simulations with 500 number of
patients. The proportion of patients assigned to treatment A (P^A), the success rates
of patients (P^S), simulated means (SM), and simulated standard errors (SSE) with
the model parameters A0 = 0, 00 = 0:25, 10 =  0:20, 20 =  0:35, 30 = 0:25,
40 = 0:15, 10 = 0:10, 20 =  1:50, 30 = 0:05, 40 = 0:05.
Quantity CARA RA CR
SM(P^A) 0.3417 0.3331 0.4996
SSE(P^A) 0.0572 0.0472 0.0222
SM(P^S) 0.4787 0.4577 0.4296
SSE(P^S) 0.0248 0.0234 0.0225
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Table 3.10: CARA, RA, and CR procedures from 3000 simulations with 500 number of
patients. Simulated means (SM), simulated standard error (SSE), estimated standard
error (ESE), and coverage probability (CP) with the model parameters A0 = 0,
00 = 0:25, 10 =  0:20, 20 =  0:35, 30 = 0:25, 40 = 0:15, 10 = 0:10, 20 =  1:50,
30 = 0:05, 40 = 0:05.
Design Quan-
tity ^A ^0 ^1 ^2 ^3 ^4 ^1 ^2 ^3 ^4
CARA SM -0.017 0.213 -0.203 -0.323 0.249 0.146 0.108 1.670 0.025 0.042
SSE 0.487 0.282 0.231 0.264 0.252 0.249 0.485 0.540 0.516 0.491
ESE 0.437 0.269 0.228 0.252 0.249 0.239 0.429 0.492 0.468 0.448
CP 0.935 0.946 0.949 0.944 0.947 0.946 0.928 0.946 0.939 0.938
RA SM -0.011 0.249 -0.205 -0.356 0.261 0.152 0.106 -1.559 0.040 0.046
SSE 0.462 0.247 0.227 0.231 0.250 0.238 0.459 0.467 0.501 0.477
ESE 0.452 0.243 0.226 0.230 0.246 0.235 0.442 0.447 0.479 0.461
CP 0.948 0.943 0.951 0.951 0.946 0.953 0.944 0.948 0.947 0.943
CR SM 0.008 0.257 -0.214 -0.361 0.265 0.156 0.112 -1.530 0.029 0.041
SSE 0.427 0.288 0.260 0.264 0.286 0.276 0.403 0.404 0.443 0.414
ESE 0.414 0.282 0.261 0.266 0.285 0.273 0.399 0.403 0.433 0.416
CP 0.944 0.947 0.956 0.951 0.952 0.948 0.944 0.951 0.939 0.954
Table 3.11: CARA, RA, and CR procedures from 3000 simulations with 1000 number
of patients. The proportion of patients assigned to treatment A in stratum h (P^Ah)
for h = 1; 2;    ;m, simulated means (SM), simulated standard errors (SSE) with
the model parameters A0 = 0, 00 = 0:25, 10 =  0:20, 20 =  0:35, 30 = 0:25,
40 = 0:15, 10 = 0:10, 20 =  1:50, 30 = 0:05, 40 = 0:05.
Stratum h
Design Quantity S1 S2 S3 S4 S5 S6 S7 S8
CARA SM(P^Ah) 0.5006 0.5036 0.5055 0.5118 0.1917 0.1997 0.1990 0.2074
SSE(P^Ah) 0.1123 0.1382 0.1437 0.1749 0.0701 0.0864 0.0910 0.1134
RA SM(P^Ah) 0.3330 0.3341 0.3359 0.3359 0.3348 0.3329 0.3339 0.3340
SSE(P^Ah) 0.0630 0.0800 0.0892 0.1166 0.0499 0.0649 0.0731 0.0942
CR SM(P^Ah) 0.4994 0.5012 0.4990 0.5004 0.4999 0.4999 0.4985 0.4972
SSE(P^Ah) 0.0547 0.0766 0.0845 0.1179 0.0440 0.0616 0.0690 0.0962
Design Quantity S9 S10 S11 S12 S13 S14 S15 S16
CARA SM(P^Ah) 0.5240 0.5270 0.5285 0.5353 0.2050 0.2123 0.2143 0.2200
SSE(P^Ah) 0.1084 0.1285 0.1384 0.1652 0.0727 0.0881 0.0944 0.1116
RA SM(P^Ah) 0.3346 0.3343 0.3311 0.3298 0.3338 0.3344 0.3330 0.3341
SSE(P^Ah) 0.0586 0.0742 0.0810 0.1082 0.0464 0.0581 0.0658 0.0866
CR SM(P^Ah) 0.5000 0.5022 0.4983 0.5014 0.5002 0.5003 0.5004 0.4980
SSE(P^Ah) 0.0497 0.0700 0.0774 0.1054 0.0412 0.0564 0.0636 0.0871
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Table 3.12: CARA, RA, and CR procedures from 3000 simulations with 1000 number
of patients. The proportion of patients assigned to treatment A (P^A), the success
rates of patients (P^S), simulated means (SM), and simulated standard errors (SSE)
with the model parameters A0 = 0, 00 = 0:25, 10 =  0:20, 20 =  0:35, 30 = 0:25,
40 = 0:15, 10 = 0:10, 20 =  1:50, 30 = 0:05, 40 = 0:05.
Quantity CARA RA CR
SM(P^A) 0.3289 0.3338 0.4999
SSE(P^A) 0.0459 0.0342 0.0161
SM(P^S) 0.4820 0.4578 0.4297
SSE(P^S) 0.0180 0.0164 0.0155
Table 3.13: CARA, RA, and CR procedures from 3000 simulations with 1000 number
of patients. Simulated means (SM), simulated standard error (SSE), estimated stan-
dard error (ESE), and coverage probability (CP) with the model parameters A0 = 0,
00 = 0:25, 10 =  0:20, 20 =  0:35, 30 = 0:25, 40 = 0:15, 10 = 0:10, 20 =  1:50,
30 = 0:05, 40 = 0:05.
Design Quan-
tity ^A ^0 ^1 ^2 ^3 ^4 ^1 ^2 ^3 ^4
CARA SM 0.002 0.229 -0.198 -0.338 0.242 0.153 0.104 -1.612 0.029 0.034
SSE 0.322 0.192 0.160 0.180 0.172 0.167 0.316 0.389 0.342 0.338
ESE 0.302 0.187 0.158 0.175 0.172 0.165 0.298 0.346 0.324 0.311
CP 0.940 0.944 0.945 0.945 0.950 0.951 0.945 0.944 0.948 0.930
RA SM 0.000 0.247 -0.197 -0.353 0.246 0.154 0.100 -1.524 0.051 0.050
SSE 0.320 0.175 0.162 0.164 0.172 0.166 0.309 0.309 0.330 0.327
ESE 0.312 0.170 0.158 0.161 0.172 0.165 0.305 0.308 0.330 0.318
CP 0.948 0.946 0.943 0.946 0.951 0.955 0.950 0.951 0.948 0.944
CR SM 0.005 0.250 -0.202 -0.352 0.250 0.156 0.099 -1.514 0.046 0.040
SSE 0.295 0.201 0.187 0.192 0.198 0.193 0.278 0.287 0.304 0.293
ESE 0.289 0.197 0.183 0.186 0.199 0.191 0.279 0.281 0.302 0.290
CP 0.945 0.947 0.941 0.945 0.950 0.952 0.949 0.945 0.953 0.953
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The values of SM(P^S) in Table 3.3 clearly show that RA and CARA designs increase
the well-being of participating patients compared to CR designs because the values
of SM(P^S) for RA, CARA, and CR designs are 77.18%, 76.02%, and 70.44%, respec-
tively. Moreover, the values of SM(P^S) for RA design is higher than CARA design.
Thus, RA design has been stably moving to achieve target allocation compared to
CARA design. On the other hand, CARA design has three dierent stages: (i) the
initial stage that is equal allocation, (ii) the second stage that attempts to detect
treatment by covariate interactions, and (iii) the nal stage that ethically reduces
the number of patients assigned to inferior treatment. That is, after identication
of treatment by covariate interactions, the success rates of participating patients are
increased by CARA designs. In fact, this result conrms the statement of Ning and
Huang (2010) that was mentioned in Section 1.4.1.
We now examine the scenario that true model contain treatment by covariate in-
teractions. The results in Tables 3.6, 3.9, and 3.12 are the scenarios for which
true models contain treatment by covariate interactions. These tables show that
CARA and RA designs generate ethically desirable outcomes compared with CR de-
sign. Moreover, CARA design are more ethical than RA designs. In this chapter,
the ethical measure is the value of SM(P^S). Also, we measure the amount of in-
teraction from origin, which is (0,0,0,0), using the Euclidean distance denoted by
EI. That is, the interaction measure is based on Euclidean distance. Therefore, EI
for Table 3.6 =
p
0:092 + ( 0:8)2 + 0:062 + 0:042 = 0.8083 and EI for Table 3.9 =p
0:12 + ( 1:5)2 + 0:052 + 0:052 = 1.5050. The dierence of ethical measure between
CARA and RA design for Table 3.6 = 67.67 - 67.50 = 0.17 and the dierence of
ethical measure between CARA and RA design for Table 3.9 = 47.87 - 45.77 = 2.1.
These results show that, the dierence in the ethical measure between CARA and RA
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designs increases when the eect of treatment by covariate interactions increase.
When we investigate Table 3.9 and 3.12, the number of participating patients are
the only dierence between these two tables. That is, the number of participating
patients in Table 3.9 is 500 and the number of participating patients in Table 3.12
is 1000. Moreover, the ethical measures for CARA, RA, and CR designs in Table
3.12 are increased by 0.33%, 0.01%, 0.01% respectively compared to Table 3.9. Thus,
CARA design generate more ethically desirable outcome compared to RA and CR
design after detecting the treatment by covariate interaction.
Because the parameter  is multi-dimensional, we use the Euclidean distance to com-
pare the consistency and asymptotic normality among designs. We dene the measure
for consistency as the Euclidean distance of SM(^) from 0, denoted by EC. The mea-
sure for normality is the Euclidean distance of CP(^) from (0:95; 0:95;    ; 0:95)0 that
is 10 1 dimension, denoted by EN. In Table 3.4, EC for CARA, RA, and CR design
are 0.1471, 0.0618, and 0.0537 respectively. In Table 3.7, EC for CARA, RA, and CR
design are 0.1633, 0.0571, and 0.0558 respectively. In the Table 3.10, EC for CARA,
RA, and CR design are 3.1705, 0.0628, and 0.0475 respectively. In the Table 3.13, EC
for CARA, RA, and CR design are 0.118, 0.0252, and 0.0195 respectively. According
to these EC values, the ML estimator under CR design is slightly more consistent
than the estimator under RA design, while the ML estimator for RA design is more
consistent than CARA design. We report the values of EN to compare normality of
ML estimators among designs. In Table 3.4, EN for CARA, RA, and CR design are
0.0291, 0.0202, and 0.0066 respectively. In Table 3.7, EN for CARA, RA, and CR
design are 0.0286, 0.0177, and 0.0073 respectively. In Table 3.10, EN for CARA, RA,
and CR design are 0.0327, 0.0133, and 0.0162 respectively. In Table 3.13, EN for
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CARA, RA, and CR design are 0.0255, 0.0123, and 0.0137 respectively. Therefore,
ML estimators slightly deviate from the normal distribution under CARA designs
compared to RA and CR designs when the number of participating patients is 500.
However, ML estimators approximately follow the normal distribution for CARA de-
sign when the number of participating patients is large. These results validate our
theoretical ndings.
3.7 Conclusion
In this chapter, we have established conditions for which ML estimators of parame-
ters in GLM for adaptive designs are consistent and asymptotically follow multivariate
normal distribution. One of these conditions is that the Fisher information matrix is
a positive denite matrix at the true vector of parameters instead of the assumption:
Fisher information and observed Fisher information matrices are positive denite ma-
trices within a neighborhood of the vector of true parameters. We have demonstrated
CARA and RA designs maximizing the well-being of participating patients in a clini-
cal trial compared to CR design by simulation studies. Moreover, RA design generates
more ethically desirable outcomes as well as ecient ML estimates than CARA design
when there is no treatment by covariate interaction in the true model. If true model
contains treatment by covariate interactions, then CARA design is more ethical than
RA design. However, ML estimates for CARA design are less ecient compared to
estimators under RA design. As we discuss in x 3.6, CARA design has three stages.
Furthermore, CARA design maximizes the well-being of participating patients in the
nal stage after treatment by covariate interactions have been detected. Based on
the above conclusions, we recommend that we can apply RA design until detecting
treatment by covariate interactions. If treatment by covarite interaction is detected,
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then we can apply CARA design in the nal stage of a clinical trial.
Chapter 4
Investigating the Performance of
Statistical Power versus Ethics
between Response-Adaptive and
Covariate-Adjusted
Response-Adaptive Designs
4.1 Introduction
In Chapter 3, we established a set of conditions for asymptotic normality and con-
sistency of estimators of regression parameters of logit model when we implement
adaptive designs that satisfy the assumption 3.4.1. In this chapter, we establish the-
oretical foundation for the power computation based on Wald statistics when the
model contains categorical variables with adaptive designs that satisfy assumption
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3.4.1. Also, one of main objectives of a clinical trial is to test treatment eect e-
ciently.
This chapter is organized as follows. In x 4.2, general results for hypotheses testing are
presented for adaptive designs and the model in (3.1) is considered as a true model.
Similar justication of the Wald type hypotheses testing procedure is discussed in x
4.3 for adaptive designs; but the model in (4.10) is considered as the true model. In
x 4.4, we investigate our theoretical results through simulation studies. At last, we
provide the conclusion in x 4.5.
4.2 Hypothesis Testing: Full Model
In general, the hypotheses test for model in (3.1) are
H0 : D0 = d0 vs HA : D0 6= d0 (4.1)
where D is an (d q) matrix of full row rank, d0 is a (d 1) constant column vector,
H0 and HA are null and alternative hypotheses respectively.
Theorem 4.2.1. We Assume 3.4.1 and 3.4.2 hold , with m <1, q <1. Dene the
Wald-type test statistic TW = [D^n d0]0[DFn(^n) 1D0] 1[D^n d0], where Fn(^n)
is the observed Fisher information matrix that is evaluated at ^n. Then, for xed n,
(a) under H0, TW converges to the central chi-square distribution with d degrees of
freedom, say, 2d;
(b) under HA, TW is asymptotically distributed as non-central chi-square distribu-
tion with d degrees of freedom, and non-centrality parameter (a), say, 2d(
(a));
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where ^n 2 G is the unrestricted MLE of 0, n  N , (a) = n[D0 d0]0[DI(0) 1D0] 1[D0 
d0], I(0) is the Fisher information matrix; G, and N is dened in Lemma 3.4.6.
Proof. From Lemma 3.4.6, Theorem 3.4.1, and Lemma 3.4.3, we have the fol-
lowing results:
(i) ^n
a:s ! 0,
(ii)
p
n(^n   0) d ! Nq[0; I(0) 1],
(iii)
1
n
Fn(0)! I(0).
Using the result (i) and the continuous mapping theorem, the following result can be
obtained
1
n
Fn(^n)
a:s:  ! 1
n
Fn(0): (4.2)
Furthermore, applying (4.2) and the result (iii), we obtain
1
n
Fn(^n)
a:s:  ! I(0): (4.3)
(a) Let ^n 2 G and n  N ,
we have that assumptions 3.4.1 and 3.4.2 are true, m < 1, q < 1; thus
Fn(^n) is a positive denite matrix [Lemma 3.4.6]. As a result, DFn(^n)
 1D0
is a positive denite matrix because D is a matrix of full row rank. Then,
[DFn(^n)
 1D0] 1 exists.
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Under H0, TW can be written as
TW = [D^n  D0]0[DFn(^n) 1D0] 1[D^n  D0]
= [
p
nD(^n   0)]0fD[(1=n)Fn(^n)] 1D0g 1[
p
nD(^n   0)]
fD[(1=n)Fn(^n)] 1D0g 1 a:s:  ! fDI(0) 1D0g 1
= D(0) 1=2D(0) 1=2; (4.4)
where D(0) = DI(0) 1D0. Since D is a (d  q) matrix of full row rank and
I(0)
 1 is a positive denite matrix, we have that D(0) is a positive denite
matrix, [Seber and Lee (2003)]. Therefore, there exists a unique square root
matrix D(0)1=2 of D(0).
Now, D is a (d  q) matrix and pn(^n   0) d ! Nq[0; I(0) 1]. Therefore, we
have
p
nD(^n 0) d ! Nd[0;D(0)] and D(0) 1=2
p
nD(^n 0) d ! Nd[0; Id]
[Srivastava (2002)], where Id is an identity matrix of dimension d. Therefore,
T W = f
p
n[D^n  D0]0g[DI(0) 1D0] 1f
p
n[D^n  D0]g
= fpn[D^n  D0]0D(0) 1=2gf
p
nD(0) 1=2[D^n  D0]g
d ! 2(d) (4.5)
where 2(d) is the central chi-square distribution with d degrees of freedom. It
follows from (4.4) and (4.5), that TW asymptotically follows the central chi-
square distribution with d degrees of freedom.
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(b) Under HA
TW = [D^n   d0]0[DFn(^n) 1D0] 1[D^n   d0]
=
p
n[D^n   d0]0[Df(1=n)Fn(^n)g 1D0] 1
p
n[D^n   d0]:
We consider
p
n[D^n   d0] =
p
n[D(^n   0) + (D0   d0)]
d ! Nd[
p
n(D0   d0);D(0)]:
Thus,
p
nD(0) 1=2[D^n   d0] d ! Nd[
p
nD(0) 1=2(D0   d0); Id]:
Therefore, following Anderson (1966)
T W = f
p
n[D^n   d0]0g[DI(0) 1D0] 1f
p
n[D^n   d0]g
= fpn[D^n   d0]0D(0) 1=2gf
p
nD(0) 1=2[D^n   d0]g
d ! 2(d)((a)); (4.6)
where (a) = n[D0   d0]0[DI(0) 1D0] 1[D0   d0]. From (4.4) and (4.6), we
have that TW asymptotically follows the non-central chi-square distribution with
d degrees of freedom, given n, and non-centrality parameter (a).
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4.2.1 Testing Interaction Eects
To test the interaction eects in (3.1), we test the following hypothesis:
H0I : 0 = 0p1 vs HAI : 0 6= 0p1: (4.7)
Choose D =

0p(q p) Ipp

, where Ipp is an identity matrix of dimension p
and d0 = 0p1, then the two hypotheses in (4.7) and (4.1) are equivalent. Dene
1
n
Fn() =
0B@ [n]11 () [n]12 ()

[n]
21 () 
[n]
22 ()
1CA, where

[n]
11 () =
1
n
nX
i=1
g(w0i)
0BBBB@
xiA xiA xiAz
0
i
xiA 1 z
0
i
xiAzi zi ziz
0
i
1CCCCA, [n]21 () = [n]12 ()0,

[n]
12 () =
1
n
nX
i=1
g(w0i)
0BBBB@
xiAz
0
i
xiAz
0
i
xiAziz
0
i
1CCCCA, and [n]22 () = 1n
nX
i=1
g(w0i)xiAziz
0
i. From The-
orem 4.2.1, when H0I is true, we have that
TWI = n[D^n   d0]0fD[(1=n)Fn(^n)] 1D0g 1[D^n   d0]
= n^
0
n[S[n]11
(^n)]^n  2p; (4.8)
where S

[n]
11
(^n) = 
[n]
22 (^n) [n]21 (^n)[[n]11 (^n)] 1[n]12 (^n).
4.2.2 Power of the Test for Interaction Eects
According to Theorem 4.2.1, when HAI is true, TWI is asymptotically distributed
as non-central chi-square distribution with p degrees of freedom, given n, and the
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non-centrality parameter , where
 = n[D0   d0]0fD[(1=n)Fn(0)] 1D0g 1[D0   d0]
= n00[S[n]11
(0)]0; (4.9)
with S

[n]
11
(0) = 
[n]
22 (0)  [n]21 (0)[[n]11 (0)] 1[n]12 (0). When we conduct the hy-
pothesis test for interaction eect in (4.7), we assume that the vector of parameters,
0I = (A0; 00;0
0)0, in model (3.1) are nuisance parameters. In practice the experi-
menter does not know the values of the nuisance parameters needed to compute power
for a real data. Also to compute the value of the non-centrality parameter  in (4.9),
Fn(0) is replaced by Fn(^n) [Demidenko (2007)].
4.3 Testing Hypotheses using the Wald-Type Statis-
tic: Reduced Model
After conducting the test for interaction eects in (4.7), if we conclude that there is
no evidence for interaction eects, one can drop the interaction terms from the full
model in (3.1) when conducting statistical inference for the main treatment eect.
Hereinafter, this sub model is called the reduced model. The reduced model is given
by
logit[P (Yi = 1jxiA; zi)] = xiAAR + 0R + z0iR;
= w0iRR; for i = 1; 2;    ; n (4.10)
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where R = (1R; 2R;    ; pR)0 are the main eects of covariates, AR is the eect of
treatment A compared to treatment B, 0R is the intercept term, wiR = (xiA; 1; z
0
i)
0,
and R = (AR; 0R;
0
R)
0. In fact, the model in (4.10) is a sub-model of the model in
3.1. In this case, we can dene the design matrix XR as
XR =
0BBBBBBBBBB@
w01R
w02R
  
  
w0nR
1CCCCCCCCCCA
:
In this subsection, we assume that the model in (4.10) is the true model and the true
vector of parameters is 0R, where 0R = (A0R; 00R;
0
0R)
0. We will investigate the
inuence of adaptation on the statistical power in testing for main eect.
Assumption 4.3.1. I(0R) is a positive denite matrix, where 0R is a (q   p)
dimensional true vector of parameters, and I(0R) is a Fisher information matrix.
4.3.1 Testing for Main Eect of Treatment
The hypothesis of interest in testing for the main eect of treatment for the model in
(4.10) becomes
H0TR : A0R = 0 HATR : A0R 6= 0: (4.11)
Now, let DR =

1 01(q p 1)

, d0R = 0, and dene
1
n
Fn(R) =
0B@ [n]11t(R) [n]12t(R)

[n]
21t(R) 
[n]
22t(R)
1CA,
where
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
[n]
11t(R) =
1
n
nX
i=1
g(w0iRR)xiA, 
[n]
22t(R) =
1
n
nX
i=1
g(w0iRR)
0B@ 1 z0i
zi ziz
0
i
1CA,

[n]
12t(R) =
1
n
nX
i=1
g(w0iRR)

xiA xiAz
0
i

, 
[n]
21t(R) = 
[n]
12t(R)
0. Under H0TR, we
have that the test statistics given by
TWR = n[DR^nR]
0fDR[(1=n)Fn(^nR)] 1D0Rg 1[DR^nR]
= n[^AnR]
2[S

[n]
22t
(^nR)]
d ! 21; (4.12)
follows the chi-squared distribution with 1 degree of freedom, where S

[n]
22t
(^nR) =

[n]
11t(^nR) [n]12t(^nR)[[n]22t(^nR)] 1[n]21t(^nR).
4.3.2 Statistical Power Computation for Hypothesis Testing
of Main Eect
It is clear that, under HATR, TWR is asymptotically distributed as non-central chi-
square with 1 degree of freedom and non-centrality parameter , given by
 = n[DR0R   d0R]0fDR[(1=n)Fn(0R)] 1D0Rg 1[DR0R   d0R]
= n[A0R]
2[S

[n]
22t
(0R)]; (4.13)
where S

[n]
22t
(0R) = 
[n]
11t(0R)   [n]12t(0R)[[n]22t(0R)] 1[n]21t(0R). In this section,
the true treatment eect, A0R, is the main parameter of interest. We refer to the
other parameters, 0NR = (00R;0R
0)0, in the model (4.10) as nuisance parameters.
The nuisance parameters, 0NR are however required for power computation in testing
the hypothesis in (4.11). Demidenko (2007) notes that to compute the value of the
non-centrality parameter  in (4.13), Fn(0R) has to be replaced by Fn(^nR).
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As dened earlier, NAh(n) is the number of patients assigned to treatment A for
a given nh number of patients in stratum h, h = 1; 2;    ;m. Dene the sample
proportion of patients (say p^Ah) assigned to treatment A for a given nh number of
patients in the stratum as p^Ah =
NAh(n)
nh
, for h = 1; 2;    ;m. Furthermore, let
p^A = (p^A1; p^A2;    ; p^Am)0 be the vector of sample proportions of patients assigned to
treatment A for a given n and A = (A(v1); A(v2);    ; A(vm))0 be the vector of
target proportions of patients assigned to treatment A over patients' strata. Then,
for a given n, we investigate the non-centrality parameter 

n
= [A0R]
2[S

[n]
22t
(0R)]; (4.14)
where S

[n]
22t
(0R) = 
[n]
11t(0R) [n]12t(0R)[[n]22t(0R)] 1[n]21t(0R),

[n]
11t(0R) =
1
n
nX
i=1
g(w0iR0R)xiA, 
[n]
22t(0R) =
1
n
nX
i=1
g(w0iR0R)
0B@ 1 z0i
zi ziz
0
i
1CA,

[n]
12t(0R) =
1
n
nX
i=1
g(w0iR0R)

xiA xiAz
0
i

, 
[n]
21t(0R) = 
[n]
12t(0R)
0.
Theorem 4.3.1. Consider the non-centrality parameter  dened in (4.14) and follow
the notation that was introduced in this section. Then,
1.  is a function of p^A, where p^A = (p^A1; p^A2;    ; p^Am)0 is the vector of sample
proportions of patients assigned to Treatment A for given n. Let this function
be (p^A).
2. (p^A) can be expressed the following quantities: the target allocation propor-
tion, the bias of the randomization procedure from the target, and the variability
induced by the randomization process.
Proof. From (4.14),

n
= [A0R]
2[S

[n]
22t
(0R)].
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1. First, we express the components of

n
, namely, 
[n]
11t(0R), 
[n]
12t(0R), 
[n]
21t(0R),
and 
[n]
22t(0R) as function of p^Ah for h = 1; 2;    ;m.

[n]
11t(0R) =
1
n
nX
i=1
g(w0iR0R)xiA
=
mX
h=1
AhR(0R)
nh
n
NAh(n)
nh
=
mX
h=1
AhR(0R)
nh
n
p^Ah

[n]
12t(0R) =
1
n
nX
i=1
g(w0iR0R)

xiA xiAz
0
i

=
mX
h=1
AhR(0R)
nh
n
NAh(n)
nh

1 v0h

=
mX
h=1
AhR(0R)
nh
n
p^Ah

1 v0h


[n]
21t(0R) =
mX
h=1
AhR(0R)
nh
n
p^Ah

1 v0h
0

[n]
22t(0R) =
1
n
nX
i=1
g(w0iR0R)
0B@ 1 z0i
zi ziz
0
i
1CA
=
mX
h=1
(0R; p^Ah)
0B@ 1 v0h
vh vhv
0
h
1CA
where (0R; p^Ah) =
nh
n
fAhR(0R)p^Ah + BhR(0R) [1  p^Ah]g,
AhR(R) = exp( AR   0R   v0hR)[1 + exp( AR   0R   v0hR)] 2, and
BhR(R) = exp( 0R   v0hR)[1 + exp( 0R   v0hR)] 2. Therefore, the non-
centrality parameter  is a function of p^A.
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2. We apply the multivariate version of Taylor's expansion to (p^A) in a neighbor-
hood centered around A. As a result,
1
n
(p^A) =
1
n
(A) +
1
n
(1)(A)[p^A   A] +
1
2
[p^A   A]0
1
n
(2)(A)[p^A   A]
+ o(k p^A   A km); where (4.15)
1
n
(1)(A) =
1
n

@(p^A)
@p^A

p^A=A
=
1
n

@(p^A)
@p^A1
@(p^A)
@p^A2
   @(p^A)
@p^Ah
   @(p^A)
@p^Am
0
p^A=A
where, for h = 1; 2;    ;m
1
n
@(p^A)
@p^Ah
= [A0R]
2
"
@S

[n]
22t
(0R; p^A)
@p^Ah
#
= [A0R]
2
"
@
[n]
11t(0R; p^A)
@p^Ah
  @
[n]
12t(0R; p^A)[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)
@p^Ah
#
= [A0R]
2
"
@
[n]
11t(0R; p^A)
@p^Ah
  @
[n]
12t(0R; p^A)
@p^Ah
[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)
#
  [A0R]2
"

[n]
12t(0R; p^A)
@[
[n]
22t(0R; p^A)]
 1
@p^Ah

[n]
21t(0R; p^A)
#
  [A0R]2
"

[n]
12t(0R; p^A)[
[n]
22t(0R; p^A)]
 1@
[n]
21t(0R; p^A)
@p^Ah
#
@
[n]
11t(0R; p^A)
@p^Ah
= AhR(0R)
nh
n
@
[n]
12t(0R; p^A)
@p^Ah
= AhR(0R)
nh
n

1 v0h

@
[n]
21t(0R; p^A)
@p^Ah
= AhR(0R)
nh
n

1 v0h
0
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@[
[n]
22t(0R; p^A)]
 1
@p^Ah
=  [[n]22t(0R; p^A)] 1
"
@[
[n]
22t(0R; p^A)]
@p^Ah
#
[
[n]
22t(0R; p^A)]
 1
=  [[n]22t(0R; p^A)] 1MDh[[n]22t(0R; p^A)] 1;
where MDh =
264nh
n
fAhR(0R)  BhR(0R)g
0B@ 1 v0h
vh vhv
0
h
1CA
375.
To evaluate the term
1
n
(2)(A) in (4.20), we require the following second deriva-
tives:
(i)
@2
[n]
11t(0R; p^A)
@p^Ah@p^Ah
= 0 for h = h or h 6= h.
(ii)
@2
[n]
12t(0R; p^A)
@p^Ah@p^Ah
= 01(p+1) for h = h or h 6= h.
(iii)
@2
[n]
21t(0R; p^A)
@p^Ah@p^Ah
= 0(p+1)1 for h = h or h 6= h.
(iv)
@2[
[n]
22t(0R; p^A)]
 1
@p^Ah@p^Ah
= 2[
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1
(v)
@2[
[n]
22t(0R; p^A)]
 1
@p^Ah@p^Ah
= [
[n]
22t(0R; p^A)]
 1MDh [
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1
+ [
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1MDh [
[n]
22t(0R; p^A)]
 1
106
1
n
(2)(A) =
1
n

@2(p^A)
@p^A@p^
0
A

p^A=A
=
1
n
0BBBBBBBBBBBBBBBB@
@2(p^A)
@p^A1@p^A1
@2(p^A)
@p^A1@p^A2
   @
2(p^A)
@p^A1@p^Ah
   @
2(p^A)
@p^A1@p^Am
@2(p^A)
@p^A2@p^A1
@2(p^A)
@p^A2@p^A2
   @
2(p^A)
@p^A2@p^Ah
   @
2(p^A)
@p^A2@p^Am
                 
@2(p^A)
@p^Ah@p^A1
@2(p^A)
@p^Ah@p^A2
   @
2(p^A)
@p^Ah@p^Ah
   @
2(p^A)
@p^Ah@p^Am
                 
@2(p^A)
@p^Am@p^A1
@2(p^A)
@p^Am@p^A2
   @
2(p^A)
@p^Am@p^Ah
   @
2(p^A)
@p^Am@p^Am
1CCCCCCCCCCCCCCCCA
p^A=A
:(4.16)
Hence the theorem holds.
4.3.3 Concaveness of the Non-centrality Parameter
We begin by noting that the theoretical non-centrality parameter . Also, we consider
only the one covariate Z1. This parameter  is a function of the sample proportion of
patients assigned to treatment A. we assume the true model
logit[P (Yi = 1jxiA)] = w0i0R for i = 1; 2;    ; n (4.17)
where 0R = (A0R; 00R; 10R)
0, wi = (xiA; 1; zi1)0. In this section, we show that
the non-centrality parameter of the distribution of the test statistic is concave, the
hypothesis test for testing treatment eect
H0T : A0R = 0 HA : A0R 6= 0; (4.18)
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where A0R is the eect of treatment A (the new treatment) compared to the eect
of treatment B (an existing treatment).
As dened earlier, NAh(n) is the number of patients assigned to treatment A for a
given nh number of patients in stratum h, h = 1; 2. Here, the sample proportion
of patients (say p^Ah) assigned to treatment A for a given nh number of patients in
the stratum is p^Ah =
NAh(n)
nh
, for h = 1; 2. Also, let p^A = (p^A1; p^A2)
0 be the vector
of sample proportions of patients assigned to treatment A for given n and A =
(A(v1); A(v2))
0, the vector of target proportions of patients assigned to treatment A
over patients' strata. From (4.14), the non-centrality parameter  for a given n is
1
n
(p^A) = [A0R]
2[S

[n]
22t
(0R; p^A)]; (4.19)
where S

[n]
22t
(0R; p^A) = 
[n]
11t(0R; p^A) [n]12t(0R; p^A)[[n]22t(0R; p^A)] 1[n]21t(0R; p^A).
Theorem 4.3.2. Consider the non-centrality parameter dened in (4.19). If we use
the notations in x 4.1, then (p^A) is a concave function.
Proof. Using the proof of Theorem 4.3.1, we have

[n]
11t(0R; p^A) =
2X
h=1
Ah(0R)
nh
n
p^Ah;

[n]
12t(0R; p^A) =
2X
h=1
Ah(0R)
nh
n
p^Ah

1 vh

;

[n]
21t(0R; p^A) =
2X
h=1
Ah(0R)
nh
n
p^Ah

1 vh
0
;

[n]
22t(0R; p^A) =
2X
h=1
h(0R)
0B@ 1 vh
vh vh
1CA ;
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where h(0R) =
nh
n
fAh(0R)p^Ah + Bh(0R) [1  p^Ah]g,
Ah(0R) = exp( A0R   00R   vh10R)[1 + exp( A0R   00R   vh10R)] 2,
Bh(0R) = exp( 00R   vh10R)[1 + exp( 00R   vh10R)] 2 for h = 1; 2; v1 = 1 and
v2 = 0.
Applying the multivariate version of Taylor's expansion to (p^A) in a neighborhood
centered around A we obtain,
1
n
(p^A) =
1
n
(A) +
1
n
(1)(A)[p^A   A] 
1
2
[p^A   A]0[ 
1
n
(2)(A)][p^A   A]
Now,
1
n
(1)(A) =
1
n

@(p^A)
@p^A

p^A=A
=
1
n

@(p^A)
@p^A1
@(p^A)
@p^A2
0
p^A=A
with
1
n
@(p^A)
@p^Ah
= [A0R]
2
"
@S

[n]
22t
(0R; p^A)
@p^Ah
#
= [A0R]
2
"
@
[n]
11t(0R; p^A)
@p^Ah
  @
[n]
12t(0R; p^A)[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)
@p^Ah
#
= [A0R]
2
"
@
[n]
11t(0R; p^A)
@p^Ah
  @
[n]
12t(0R; p^A)
@p^Ah
[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)
#
  [A0R]2
"

[n]
12t(0R; p^A)
@[
[n]
22t(0R; p^A)]
 1
@p^Ah

[n]
21t(0R; p^A)
#
  [A0R]2
"

[n]
12t(0R; p^A)[
[n]
22t(0R; p^A)]
 1@
[n]
21t(0R; p^A)
@p^Ah
#
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where
@
[n]
11t(0R; p^A)
@p^Ah
= Ah(0R)
nh
n
@
[n]
12t(0R; p^A)
@p^Ah
= Ah(0R)
nh
n

1 vh

@
[n]
21t(0R; p^A)
@p^Ah
= Ah(0R)
nh
n

1 vh
0
and
@[
[n]
22t(0R; p^A)]
 1
@p^Ah
=  [[n]22t(0R; p^A)] 1
"
@[
[n]
22t(0R; p^A)]
@p^Ah
#
[
[n]
22t(0R; p^A)]
 1
=  [[n]22t(0R; p^A)] 1MDh[[n]22t(0R; p^A)] 1;
MDh =
264nh
n
fAh(0R)  Bh(0R)g
0B@ 1 vh
vh vh
1CA
375.
We note that here, h = 1; 2, and v1 = 1, v2 = 0. Also,
1
n
(2)(A) =
1
n

@2(p^A)
@p^A@p^
0
A

p^A=A
=
1
n
0BB@
@2(p^A)
@p^A1@p^A1
@2(p^A)
@p^A1@p^A2
@2(p^A)
@p^A2@p^A1
@2(p^A)
@p^A2@p^A2
1CCA
p^A=A
: (4.20)
To evaluate the term
1
n
(2)(A) in 4.20, we require the following second derivatives:
(i)
@2
[n]
11t(0R; p^A)
@p^Ah@p^Ah
= 0 for h = h or h 6= h,
(ii)
@2
[n]
12t(0R; p^A)
@p^Ah@p^Ah
= 012 for h = h or h 6= h,
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(iii)
@2
[n]
21t(0R; p^A)
@p^Ah@p^Ah
= 021 for h = h or h 6= h, and
(iv)
@2[
[n]
22t(0R; p^A)]
 1
@p^Ah@p^Ah
= 2[
[n]
22t(0R; p^A)]
 1MDh [
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1
for h = h or h 6= h.
The second derivatives in (4.20) are then, given by
1
n
@2(p^A)
@p^Ah@p^Ah
= 2[A0R]
2

AhR(0R)
nh
n

1 vh

[
[n]
22t(0R; p^A)]
 1MDh [
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)

  2[A0R]2

AhR(0R)
nh
n

1 vh

[
[n]
22t(0R; p^A)]
 1AhR(0R)
nh
n

1 vh
0
+ 2[A0R]
2

AhR(0R)
nh
n

1 vh

[
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)

  2[A0R]2
h

[n]
12t(0R; p^A)[
[n]
22t(0R; p^A)]
 1MDh [
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1
i

[n]
21t(0R; p^A);
1
n
@2(p^A)
@p^Ah@p^Ah
= 2[A0R]
2

Ah(0R)
nh
n

1 vh

[
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)

  2[A0R]2

Ah(0R)
nh
n

1 vh

[
[n]
22t(0R; p^A)]
 1Ah(0R)
nh
n

1 vh
0
+ 2[A0R]
2

Ah(0R)
nh
n

1 vh

[
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)

  2[A0R]2
h

[n]
12t(0R; p^A)[
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1MDh[
[n]
22t(0R; p^A)]
 1
i

[n]
21t(0R; p^A):
111
Using the fact that v1 = 1, v2 = 0, we obtain the following results

[n]
22t(0R; p^A) =
2X
h=1
h(0R)
0B@ 1 vh
vh vh
1CA
= 1(0R)
0B@ 1 1
1 1
1CA+ 2(0R)
0B@ 1 0
0 0
1CA
=
0B@ 1(0R) + 2(0R) 1(0R)
1(0R) 1(0R)
1CA ;
with

[n]
22t(0R; p^A)
 1 =
1
1(0R)2(0R)
0B@ 1(0R)  1(0R)
 1(0R) 1(0R) + 2(0R)
1CA :
Recall that
MDh =
264nh
n
fAh(0R)  Bh(0R)g
0B@ 1 vh
vh vh
1CA
375
= h(0R)
0B@ 1 vh
vh vh
1CA ;
where h(0R) =
nh
n
fAh(0R)  Bh(0R)g, and

[n]
12t(0R; p^A) =
2X
h=1
Ah(0R)
nh
n
p^Ah

1 vh

=
2X
h=1
Ch(0R)

1 vh

=

C1(0R) + C2(0R) C1(0R)

12
;
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where Ch(0R) = Dh(0R)p^Ah and Dh(0R) = Ah(0R)
nh
n
. It follows that,
[
[n]
22t(0R; p^A)]
 1MD1[
[n]
22t(0R; p^A)]
 1
=
1(0R)
[1(0R)2(0R)]
0B@ 1(0R)  1(0R)
 1(0R) 1(0R) + 2(0R)
1CA
0B@ 1 1
1 1
1CA [[n]22t(0R; p^A)] 1
=
1(0R)
[1(0R)]22(0R)
0B@ 0 0
1 1
1CA
0B@ 1(0R)  1(0R)
 1(0R) 1(0R) + 2(0R)
1CA
=
1(0R)
[1(0R)]2
0B@ 0 0
0 1
1CA ;
[
[n]
22t(0R; p^A)]
 1MD2[
[n]
22t(0R; p^A)]
 1
=
2(0R)
[1(0R)2(0R)]
0B@ 1(0R)  1(0R)
 1(0R) 1(0R) + 2(0R)
1CA
0B@ 1 0
0 0
1CA [[n]22t(0R; p^A)] 1
=
2(0R)
1(0R)[2(0R)]2
0B@ 1 0
 1 0
1CA
0B@ 1(0R)  1(0R)
 1(0R) 1(0R) + 2(0R)
1CA
=
2(0R)
[2(0R)]2
0B@ 1  1
 1 1
1CA ;
[
[n]
22t(0R; p^A)]
 1MD1[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)
=
1(0R)
[1(0R)]2
0B@ 0 0
0 1
1CA
0B@ C1(0R) + C2(0R)
C1(0R)
1CA = 1(0R)C1(0R)
[1(0R)]2
0B@ 0
1
1CA ;
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[
[n]
22t(0R; p^A)]
 1MD2[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)
=
2(0R)
[2(0R)]2
0B@ 1  1
 1 1
1CA
0B@ C1(0R) + C2(0R)
C1(0R)
1CA
=
2(0R)C2(0R)
[2(0R)]2
0B@ 1
 1
1CA ;

[n]
12t(0R; p^A)[
[n]
22t(0R; p^A)]
 1MD1[
[n]
22t(0R; p^A)]
 1MD1[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)
=
[1(0R)]
2
[1(0R)]2

[n]
12t(0R; p^A)
0B@ 0 0
0 1
1CA
0B@ 1 1
1 1
1CA [[n]22t(0R; p^A)] 1[n]21t(0R; p^A)
=
[1(0R)]
2
[1(0R)]3
1
2(0R)

[n]
12t(0R; p^A)
0B@ 0 0
1 1
1CA
0B@ 1(0R)  1(0R)
 1(0R) 1(0R) + 2(0R)
1CA

[n]
21t(0R; p^A)
=
[1(0R)]
2
[1(0R)]3

C1(0R) + C2(0R) C1(0R)
0B@ 0 0
0 1
1CA[n]21t(0R; p^A)
=
[1(0R)]
2
[1(0R)]3
C1(0R)

0 1
0B@ 0 0
0 1
1CA[n]21t(0R; p^A)
=
[1(0R)]
2
[1(0R)]3
C1(0R)

0 1
0B@ C1(0R) + C2(0R)
C1(0R)
1CA
=
[1(0R)]
2
[1(0R)]3
[C1(0R)]
2:
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The elements of (4.20) can be further simplied as follows:

[n]
12t(0R; p^A)[
[n]
22t(0R; p^A)]
 1MD2[
[n]
22t(0R; p^A)]
 1MD2[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)
=
[2(0R)]
2
[2(0R)]2

[n]
12t(0R; p^A)
0B@ 1  1
 1 1
1CA
0B@ 1 0
0 0
1CA [[n]22t(0R; p^A)] 1[n]21t(0R; p^A)
=
[2(0R)]
2
[1(0R)][2(0R)]3

[n]
12t(0R; p^A)
0B@ 1 0
 1 0
1CA
0B@ 1(0R)  1(0R)
 1(0R) 1(0R) + 2(0R)
1CA

[n]
21t(0R; p^A)
=
[2(0R)]
2
[2(0R)]3

C1(0R) + C2(0R) C1(0R)
0B@ 1  1
 1 1
1CA[n]21t(0R; p^A)
=
[2(0R)]
2
[2(0R)]3
C2(0R)

1  1
0B@ C1(0R) + C2(0R)
C1(0R)
1CA
=
[2(0R)]
2
[2(0R)]3
[C2(0R)]
2;
MD2[
[n]
22t(0R; p^A)]
 1MD1
=
2(0R)1(0R)
1(0R)2(0R)
0B@ 1 0
0 0
1CA
0B@ 1(0R)  1(0R)
 1(0R) 1(0R) + 2(0R)
1CA
0B@ 1 1
1 1
1CA
=
2(0R)1(0R)
2(0R)
0B@ 1  1
0 0
1CA
0B@ 1 1
1 1
1CA
=
0B@ 0 0
0 0
1CA ;
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1
n
@2(p^A)
@p^A1@p^A1
= 2[A0R]
2

D1(0R)

1 1

[
[n]
22t(0R; p^A)]
 1MD1[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)

  2[A0R]2

[D1(0R)]
2

1 1

[
[n]
22t(0R; p^A)]
 1

1 1
0
+ 2[A0R]
2

D1(0R)

1 1

[
[n]
22t(0R; p^A)]
 1MD1[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)

  2[A0R]2
h

[n]
12t(0R; p^A)[
[n]
22t(0R; p^A)]
 1MD1[
[n]
22t(0R; p^A)]
 1MD1[
[n]
22t(0R; p^A)]
 1
i

[n]
21t(0R; p^A)
= 2[A0R]
2D1(0R)

1 1
0B@ 0
1
1CA 1(0R)C1(0R)
[1(0R)]2
  2[A0R]2[D1(0R)]2 1
1(0R)2(0R)

1 1
0B@ 1(0R)  1(0R)
 1(0R) 1(0R) + 2(0R)
1CA
0B@ 1
1
1CA
+ 2[A0R]
2D1(0R)

1 1
0B@ 0
1
1CA 1(0R)C1(0R)
[1(0R)]2
  2[A0R]2 [1(0R)]
2
[1(0R)]3
[C1(0R)]
2
=  2[A0R]
2
1(0R)

[D1(0R)]
2   2D1(0R)1(0R)C1(0R)
1(0R)
+
[1(0R)]
2
[1(0R)]2
[C1(0R)]
2

=  2[A0R]
2
1(0R)

D1(0R)  1(0R)
1(0R)
C1(0R)
2
;
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1
n
@2(p^A)
@p^A2@p^A2
= 2[A0R]
2

D2(0R)

1 0

[
[n]
22t(0R; p^A)]
 1MD2[
[n]
22t(0R; p^A)]
 1[n]21t(0R; p^A)

  2[A0R]2

[D2(0R)]
2

1 0

[
[n]
22t(0R; p^A)]
 1

1 0
0
+ 2[A0R]
2

D2(0R)

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Since
1
n
@2(p^A)
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=  2[A0R]
2
1(0R)

D1(0R)  1(0R)
1(0R)
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1
n
@2(p^A)
@p^A2@p^A2
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2
2(0R)

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1
n
@2(p^A)
@p^A1@p^A2
= 0;
1
n
@2(p^A)
@p^A2@p^A1
= 0:
The determinant of
1
n
(2)(A) in (4.20) is positive and
1
n
@2(p^A)
@p^A1@p^A1
is negative. That
is,
1
n
(2)(p^A) is a negative denite matrix. Therefore, (p^A) is a concave function.
For an example, we choose the values for true parameters: A = 1:5, 0 = 0:6, and
1 =  0:4 to draw the three dimensional graph of 1
n
(A) versus A = (A(v1); A(v2))
0
when the number of participating patients is 500. This graph is in the Figure 4.1.
This graph conrms the concaveness of the non-centrality parameter that is a function
of the proportion of treatment assignment.
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Figure 4.1: The graph of concaveness
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4.4 Simulation Studies
In this section, we validate our theoretical results through simulation studies. We
follow the same description and choice of true parameters used in x 3.6 for our sim-
ulation studies. Moreover, we verify whether the test statistic has valid the Type I
error and discuss the computation of statistical power to apply for real data. The
statistical power and Type I error rates are compared among three designs that were
discussed in Chapter 3.
To verify the Type I error rates, data was generated under the null hypothesis H0I .
We then estimate the size of the test, , by computing the proportion of rejections
of H0I for a xed value 
. We consider a test of the hypothesis for treatment by
covariate interactions in the logit model dened in (3.1).
H0I : 0 = 041 HAI : 0 6= 041 (4.21)
where 0 = (10; 20; 30; 40)
0. We use the Wald test that was derived in Section 4.2.1.
Thus, the Wald test statistic for testing the hypothesis in (4.21) is
TWI = n^
0
n[S[n]11
(^n)]^n  24;: (4.22)
The rejection region for the test in (4.21) are
fTWI : TWI < 24;=2 or TWI > 24;(1 =2)g; (4.23)
where P [TWI < 
2
4;=2] = 
=2 and P [TWI < 24;1 =2] = 1  =2. We consider two
scenarios to conrm whether Type I error is controllable for testing the hypothesis in
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4.21. These results are outlined in Table 4.1 and 4.2.
Table 4.1: CARA, RA, and CR procedures from 10000 simulations with 500 number of
patients. Size of the test () and estimated size of the test (^) with model parameters
A0 = 1:00, 00 = 0:50, 10 =  0:18, 20 =  0:30, 30 = 0:25, 40 = 0:10, 10 = 0:00,
20 = 0:00, 30 = 0:00, 40 = 0:00.
Design  ^ ^   
CARA 0.10 0.1102 0.0102
0.05 0.0517 0.0017
0.01 0.0095 -0.0005
RA 0.10 0.0936 -0.0064
0.05 0.0462 -0.0038
0.01 0.0097 -0.0003
CR 0.10 0.0946 -0.0054
0.05 0.0471 -0.0029
0.01 0.0100 0.0000
Table 4.2: CARA, RA, and CR procedures from 10000 simulations with 500 number of
patients. Size of the test () and estimated size of the test (^) with model parameters
A0 = 0:50, 00 = 0:50, 10 =  0:18, 20 =  0:30, 30 = 0:25, 40 = 0:10, 10 = 0:00,
20 = 0:00, 30 = 0:00, 40 = 0:00.
Design  ^ ^   
CARA 0.10 0.1059 0.0059
0.05 0.0540 0.004
0.01 0.0116 0.0016
RA 0.10 0.0935 -0.0065
0.05 0.0481 -0.0019
0.01 0.0085 -0.0015
CR 0.10 0.0966 -0.0034
0.05 0.0464 -0.0036
0.01 0.0088 -0.0012
In CARA designs, the estimated size of errors are slightly higher than the true size of
error; reverse results are generated by RA and CR designs. But, these three designs
control Type I error because there is no signicant deviation between the actual size
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of test and estimated size of test.
Table 4.3: CARA, RA, and CR procedures from 5000 simulations with 500 number of
patients and 0.05 size of the test. Power computation testing interaction with model pa-
rameters A0 = 0:50, 00 = 0:25, 10 =  0:20, 20 =  0:40, 30 = 0:35, 40 = 0:20,
0 = (10; 20; 30; 40)
0.
Average Overall
Simulated Conventional Error Design Success
0 Design Power Power Variability Rates
(0:10; 1:50; 0:00; 0:00)0
CARA 0.7902 0.7186 0.0716 0.1559 0.5112
RA 0.8068 0.7843 0.0225 0.1119 0.4851
CR 0.8262 0.8103 0.0159 0.1038 0.4796
(0:10; 1:50; 0:35; 0:00)0
CARA 0.7984 0.7271 0.0713 0.1564 0.5193
RA 0.8112 0.7928 0.0184 0.1127 0.4929
CR 0.8284 0.8113 0.0171 0.1038 0.4903
(0:30; 1:20; 0:35; 0:20)0
CARA 0.6240 0.5643 0.0597 0.1569 0.5466
RA 0.6318 0.6220 0.0098 0.1135 0.5280
CR 0.6426 0.6231 0.0195 0.1038 0.5284
(0:20; 2:00; 0:07; 0:05)0
CARA 0.9608 0.8666 0.0942 0.1471 0.5152
RA 0.9708 0.9481 0.0227 0.1108 0.4742
CR 0.9774 0.9709 0.0065 0.1038 0.4621
Table 4.4: CARA, RA, and CR procedures from 5000 simulations with 1000 number
of patients and 0.05 size of the test. Power computation testing interaction with model
parameters A0 = 0:50, 00 = 0:25, 10 =  0:20, 20 =  0:40, 30 = 0:35, 40 = 0:20,
0 = (10; 20; 30; 40)
0.
Average Overall
Simulated Conventional Error Design Success
0 Design Power Power Variability Rates
(0:10; 1:50; 0:00; 0:00)0
CARA 0.9916 0.9720 0.0196 0.1170 0.5131
RA 0.9912 0.9891 0.0021 0.0784 0.4849
CR 0.9944 0.9923 0.0021 0.0724 0.4791
(0:10; 1:50; 0:35; 0:00)0
CARA 0.9930 0.9756 0.0174 0.1173 0.5214
RA 0.9960 0.9902 0.0058 0.0788 0.4933
CR 0.9948 0.9923 0.0025 0.0722 0.4901
(0:30; 1:20; 0:35; 0:20)0
CARA 0.9450 0.9120 0.0330 0.1170 0.5478
RA 0.9550 0.9442 0.0107 0.0795 0.5279
CR 0.9540 0.9438 0.0102 0.0724 0.5279
(0:20; 2:00; 0:07; 0:05)0
CARA 0.9998 0.9893 0.0105 0.1103 0.5190
RA 0.9996 0.9998 -0.0002 0.0774 0.4742
CR 1.000 1.0000 0.0000 0.0724 0.4616
We justify the power computation method discussed in x 4.2.2 by simulation study.
So, data was generated under the alternative hypothesis in (4.21). Simulated power is
calculated by the proportion of rejections using the rejection region in (4.23). On the
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other hand, we use the power computation method in x 4.2.2 to calculate statistical
power to each simulation. Then, we calculate the average of these calculated powers
and this power is called the conventional power. According to Demidenko (2007),
there is no exact method to compute the statistical power for test in (4.21) because
of nuisance parameters. The null model approach was used to estimate nuisance pa-
rameters in earlier literatures [see Whittemore (1981) and Self and Mauritsen (1988)
]. So, estimation of nuisance parameters has not ended up in research of statistical
power computation, particularly for a small sample and continuous covariates. In this
simulation study, we are interested in comparing the statistical powers among three
designs: CARA, RA, and CR designs. Because the power computation in x 4.2.2 is
an approximate method, thus we compute error that is the dierence between the
simulated power and the conventional power.
The simulated powers in Tables 4.3 and 4.4 show that CR designs have more statisti-
cal powers than RA and CARA designs. Furthermore, RA designs are more ecient
than CARA designs. When we examine the errors among three designs, CARA de-
signs create more errors than RA and CR designs; also RA designs generate more
errors compared to CR designs because CARA designs create more treatment im-
balances over the covariate proles [see Tables 3.5, 3.8, and 3.11]. However, ethical
measures [Overall Success Rates] demonstrate reverse conclusions. Therefore, CARA
designs are more ethical compared to RA and CR designs if true model contains treat-
ment by covariate interactions. When we increase the number of patients from 500 to
1000, then (i) simulated powers increase, and (ii) errors decrease [see Tables 4.3 and
4.4].
We dene the design variability for stratum h is SSE(P^Ah) for h = 1; 2;    : Then, the
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average design variability is calculated using the formula
mX
h=1
P^Ah=m. The results in
Tables 4.3 and 4.4 show that the simulated power increases when the average design
variability decreases. Moreover, CARA designs have more design variabilities than
RA and CRD designs.
4.5 Conclusion
In this chapter, we have justied using the Wald test for adaptive designs when the
sample size is large. We have discussed the power computation method for real data,
and this method is an approximation to compute statistical power. Moreover, we
have veried that the power calculation based on this approach generates values close
to exact power when the sample size increases. Thus, we can use this power compu-
tation method to calculate power when we do sequential analysis in a clinical trial.
We have proved that the statistical power depends on adaptive designs through the
non-centrality parameter. In fact, we have demonstrated that this non-centrality
parameter is a function of proportions of patients assigned to treatments over the
covariate proles. Furthermore, we have proved that this function is concave when we
assume the logit model as an ideal model with binary covariates. Also, we have shown
this non-centrality parameter depends on these quantities: the target allocation pro-
portion, the bias of the randomization procedure from the target, and the variability
induced by the randomization process.
Although CARA designs have less eciency compare to RA and CR designs, CARA
designs generate more ethically desirable outcomes than RA and CR designs if the
exact model contains treatment by covariates interactions. The power of hypothesis
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testing increases when design variability decreases. Further research requires extend-
ing Theorem 4.3.2 for more than one categorical covariates.
Chapter 5
Discussion and Conclusions
5.1 An overview for the contribution of this thesis
Treatment assignment methods play a signicant role in an ecient statistical infer-
ence and the ethics of participating patients in clinical trials. Moreover, the ecient
statistical inference is essential for the well-being of future patients. Adaptive de-
signs are used to achieve these eciencies and ethics goals. It is in interest to de-
velop adaptive design methods to maximize the well-being of participating patients.
Furthermore, Response-Adaptive (RA) and Covariate-Adjusted Response-Adaptive
(CARA) designs are used to increase the well-being of participating patients. Also,
the RA designs have been well established with the assumption of simple homoge-
neous parametric structure. The limited number of researchers have developed under
the assumption of non-homogeneous parametric structure for RA designs. Due to in-
creasing discoveries of biomarkers and identication of the observed diversity among
patients, personalized medicine has interested to extend human life expectancy. In
fact, these factors which are biomarkers and the observed heterogeneity among pa-
tients are covariates. Meanwhile, these covariates are used to achieve the ethics goals
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for participating patients. CARA designs were developed to get benets using covari-
ates in randomization to maximize the well-being of participating patients.
We have investigated the performance of RA designs when a generalized linear mixed
model (GLMM) is an ideal model. We have considered a logit model to examine the
ethics of participating patients. We have shown that the estimators of model parame-
ters are consistent and follow asymptotically normal distribution when the number of
patients is assumed to be constant at each medical center. Also, we have introduced
the new searching method to estimate of model parameters based on the inuence
function approach and derived a closed form expression for the asymptotic variance
of the regression parameter estimators. Moreover, we have demonstrated that this
searching method works better than Hessian matrix approach. We have veried that
RA designs generate ethically desirable outcome compared to CR design by conduct-
ing simulation studies.
We have examined the performance of RA, CARA, and CR designs, for which re-
sponses come from GLM, measuring these quantities: (i) eciency of statistical in-
ference, and (ii) ethics of participating patients. Thus, we have considered the logit
model with categorical covariates to investigate these designs. Furthermore, we have
proved that the ML estimators of model parameters are consistent and follow asymp-
totically multivariate Gaussian distribution for adaptive designs. According to the
present literature, when we study the large sample behavior of ML estimators for
model parameters, a regularity assumption: the Fisher information and ob-
served Fisher information matrices are positive denite within a neighbor-
hood near to vector of ideal parameters is necessary to examine the asymptotic
properties of these estimators. In fact, the boundary of the area is not exactly dened,
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and this assumption is a strong assumption. Thus, we have proved that an assump-
tion: the Fisher information matrix at the ideal vector of parameters is a positive
denite matrix is sucient to investigate the asymptotic properties of ML estimators.
We have demonstrated that RA design generates ethically desirable outcomes as well
as more statistical eciency compared to CARA design if there is no treatment by co-
variate interactions in an ideal model. Also, when a perfect model contains treatment
by covariate interactions, CARA design is more ethical than RA design; however, RA
design has more statistical power than CARA design.
We have justied that the Wald-type of test can be asymptotically applied for a
general class of adaptive designs. Moreover, the power computation method has been
discussed for adaptive designs when a logit model is an exact model. Also, we have
veried that this power calculation method generates exact statistical power for a
large number of participating patients based on simulation results. We have shown
that the choice of adaptive designs aects the statistical power of hypothesis testing.
Moreover, we have theoretically shown that the statistical power decreases with design
variabilities of adaptive designs for which a covariate is in a logit model. Moreover,
the simulation results have conrmed this behavior between statistical power and
design variability for more than one covariates. Thus, our simulation results validate
the feasibility of logical proof for which the statistical power decreases when design
variability increases for more than one covariate. Therefore, we conclude this chapter
by discussing some future works including the behavior of the statistical power and
design variability.
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5.2 Future Works
Based on contributions of this thesis, we discuss some future works to extend this
research.
We have assumed that treatment assignment and center eects only inuence response
to investigate the performance of RA designs in a multi-center clinical trial in Chapter
2. Treatment eect can be eciently estimated when we include covariates of patients
in a model. The investigation of large sample properties of ML estimators for model
parameters we have developed using the inuence function method can be extended
to generalized linear mixed models for the exponential family including covariates.
We will examine the performance of the iteration method that we have introduced
based on the inuence function method and iteration method based on the Hessian
matrix for GLM.
Many adaptive designs satisfy the Assumption 3.4.1 in Chapter 3. For instance, we
will provide a logical proof for which the response adaptive (RA) and the covariate
adaptive (CA) designs based the minimization method satisfy the Assumption 3.4.1
in Chapter 3. As we mentioned in x 5.1, we will theoretically show that the statistical
power increases when the design variability decreases for more than one categorical
covariates. CA designs are used in a clinical trial to improve the ecient statistical
inference. In fact, the equal allocation has less eciency compared to CA design.
Thus, the design variability of CA design is smaller than CR design. We will demon-
strate this conclusion using simulation study.
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